Document:

EX-10.19(i)

 Exhibit 10.19(i) 

TECHNOLOGY LICENSE AGREEMENT 
 THIS
AGREEMENT is made and effective as of the 21st day of July, 2005 
 BETWEEN: 

THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION, a corporation without share capital incorporated under the laws of the Province of
Ontario whose full post office address is Suite 200, 243 College Street, Toronto, Ontario M5T 1 R5, Canada 
 (hereinafter
“UTIF”) 
 - and- 

PROTAGENIC THERAPEUTICS, INC., a corporation incorporated under the laws of Delaware and having a principal place of business at 4264
Corte Favor, San Diego, California 92130 U.S.A. 
 (hereinafter “Licensee”) 

WHEREAS David Lovejoy, Dalia Barsyte, Susan Rotzinger and Bradley Chewpoy (hereinafter “Owners”), while employed by the University (as
hereinafter defined), made an invention titled “Teneurin C-Terminal Associated Peptides (TCAP) and Methods and Uses Thereof” and certain improvements thereto (hereinafter “Invention”); 

WHEREAS David Lovejoy, while employed by the University, also made an invention titled “Selected Targeting of Residue Motifs (STORM): A Novel
Algorithmic Method to Predict Bioactive Peptides in Genome Databases”, (hereinafter “STORM”); 
 WHEREAS by an Assignment of
Rights from the University dated December 12, 2001 and an Assignment of Rights from the University dated July 4, 2003, the University assigned its entire right, title and interest in the Invention to Owners on terms and conditions set out
therein; 
 WHEREAS by an Assignment of Rights from the University dated December 15, 2004, the University assigned its entire right, title and
interest in STORM to David Lovejoy on terms and conditions set out therein; 
 WHEREAS by a Technology Owners’ Agreement dated March 8,
2002 as amended January 30, 2004, April 28, 2005 and July 20, 2005, the Owners retained UTIF as their agent for the exploitation of the Invention, including the patenting and licensing thereof; 

  
 Page 1 of 24 

 WHEREAS by an Technology Owners’ Agreement dated July 20, 2005, David Lovejoy retained UTIF
as his agent for the exploitation of STORM, including the patenting and licensing thereof; 
 WHEREAS UTIF, on behalf of the Owners, has filed patent
applications in relation to the Invention as listed in Schedule A; 
 WHEREAS Licensee is a company whose purpose is to develop and commercialize
novel drugs; 
 WHEREAS Licensee wishes to commercialize, develop, manufacture, market, distribute and sell products which may be developed through
the use of a part or the whole of the Technology, as hereinafter defined, and therefore desires to obtain a license for the Technology; and 
 WHEREAS
UTIF is willing to grant a license under the terms and conditions set forth hereinafter. 
 NOW THEREFORE in consideration of the premises and
the mutual covenants, terms, conditions and agreements contained herein, and other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows: 

ARTICLE 1 

INTERPRETATION 
  

	1.1	Definitions 

 In this Agreement, the following terms have the meanings set forth below unless there is
something in the subject matter or context inconsistent therewith: 
 “Affiliate” shall mean any company or other legal entity controlling,
controlled by or under common control with Licensee. The term “control” means the ability to direct the management and policies of said entity, whether through ownership of equity, by contract or otherwise; 

“Agreement” means this Technology License Agreement including all attached schedules, as the same may be supplemented, amended, restated or
replaced in writing from time to time; 
 “Calendar Quarter” shall mean the period of time ending on
March 31, June 30, September 30 and December 31 of each year; 
 “Confidential Information” means this
Agreement and its terms and conditions, the Knowhow, and any information, which is non-public, confidential or proprietary in nature, including, without limitation, business information, trade secrets, and any information related to the Technology,
whether written, oral or in electronic form, provided that tangible materials are marked as confidential, and provided that information given orally is identified as confidential at the time of disclosure, and confirmed as confidential in writing
within fifteen (15) days, but shall not include information that: 

  
 Page 2 of 24 

	 	(a)	is or becomes generally available to the public other than as a result of any act by a Party to this Agreement; 

  

	 	(b)	is rightfully received from a Third Party without similar restriction or without breach of this Agreement; 

  

	 	(c)	a Party is able to demonstrate, in writing, was known to it on a non-confidential basis; or 

  

	 	(d)	was independently developed by a Party without the use of any of the Confidential Information. 

“Effective Date” shall mean the date first shown in this Agreement; 

“Field of Use” shall mean all human therapeutic applications; 

“First Commercial Sale” means the first sale of a Licensed Product in the Territory after Regulatory Approval (as hereinafter defined), by
Licensee or its Affiliates (or their sub-licensee(s)) to any Third Party as evidenced by an invoice or other relevant document to such Third Party. A sale shall not include Licensed Products delivered solely for research purposes or for clinical
trials or Licensed Products distributed as samples or promotions; 
 “Improvements” means any and all improvements, variations, updates,
modifications or enhancements to the Technology which are developed under the terms of a research agreement dated December 14, 2004, as amended May 31, 2005, between Licensee and the Governing Council of the University of Toronto attached
hereto as Schedule B; 
 “Intellectual Property Rights” means any and all proprietary rights provided under, (i) patent law,
(ii) copyright law, (iii) trade-mark law, (iv) design patent or industrial design law, (v) integrated circuit topography or mask work law, or (vi) any other statutory provision or common law principle applicable to this
Agreement, including trade secret law, which may provide a right in either ideas, formulae, algorithms, concepts, inventions or know-how generally, or the expression or use of such ideas, formulae, algorithms, concepts, inventions or know-how; 

“Know-how” means any and all trade secrets, technical expertise, knowledge, confidential information and know-how, whether patentable or
unpatentable relating to the Patents and/or STORM, whether in written, machine readable, drawing or oral form, including, without limiting the generality of the foregoing, all technical information, raw material, data, product specifications,
processes and designs, operating and production data, calculations, computer programs, instructions and techniques, quality control and other standards, and drawings relating thereto whether developed by UTIF, an Owner or the Licensee that exists as
of the date of this Agreement; 

  
 Page 3 of 24 

 “Licensed Product” means (i) any product derived from STORM; (ii) any product derived
from an Improvement; and/or (iii) any product derived from, or partially from, at least one claim of the Patents; 
 “Milestones”
refers to the events which the Licensee has agreed to accomplish within defined periods of time. The Milestones are described in Schedule C of this Agreement; 

“Net Sales” means the gross amount received by Licensee, its Affiliates or sub-licensees (including, without limitation, the fair market
value of any non-cash consideration received in connection therewith) net of any of the following charges or expenses that are incurred in connection with the sales, leases or other transfers of Licensed Products: (i) discounts (including cash
discounts and quantity discounts), chargeback payments and rebates granted to healthcare organizations or to federal, state or local government (or their respective agencies, purchasers and reimbursers) or to trade customers; (ii) credits,
rebates or allowances because of damaged goods or returns with respect to Licensed Products; (iii) freight, postage, shipping and insurance charges incurred in transporting the Licensed Product(s) to the end customer; and (iv) taxes,
duties or other governmental charges (other than income taxes) levied on, absorbed or otherwise imposed on sales of Licensed Products; 

“Parties” means UTIF and the Licensee collectively, and “Party” means one of them; 

“Patents” means the patent application listed in Schedule A appended hereto and any patents and patent applications from which such patent
application claims priority, and shall include any divisional, re-examination, renewal, or continuation applications based on any of the foregoing patents and patent applications, any patents which may issue on, from or as a result of any of the
foregoing, and any reissue of said patents; 
 “Phase I End” means approval by the FDA or other applicable regulatory authority to commence
Phase II Clinical Trials of a Licensed Product as such trials are described in 21 C.F.R. 312.21(b); 
 “Phase II End” means approval by the
FDA or other applicable regulatory authority to commence Phase III Clinical Trials of a Licensed Product as such trials are described in 21 C.F.R. 312.21(c); 

“Phase III End” means Regulatory Approval of a Licensed Product; 

“Prime Rate” for any day means the rate of interest expressed as a rate per annum that The Royal Bank of Canada establishes at its head
office in Toronto as the reference rate of interest that it will charge on that day for Canadian dollar demand loans to its customers in Canada and which it at present refers to as its prime rate; 

“Regulatory Approval” means all governmental approvals and authorizations necessary for the manufacture and commercial sale of the Licensed
Product in a country of the Territory; 

  
 Page 4 of 24 

 “Secure” means the terms of financing agreed to as witnessed by a signed private placement
memorandum (PPM) or term sheet and funds in escrow and accessible by Licensee within thirty (30) days following the execution of the PPM or term sheet; 

“STORM” means the invention titled “Selected Targeting of Residue Motifs: A Novel Algorithmic Method to Predict Bioactive Peptides in
Genome Databases” as described in the University of Toronto Confidential Invention Disclosure appended hereto as Schedule D; 

“Technology” means the Patents, STORM, Know-how and, subject to Section 4.4 herein, Improvements; 

“Territory” means each and every country of the world; 

“Third Party” means, in respect of a Party, a person who deals with such Party at arm’s length, as that term is defined in the Income
Tax Act (Canada) on the date hereof; and 
 “University” means the University of Toronto. 

 

	1.2	Captions 

 Captions or descriptive words at the commencement of the various sections are inserted for
convenience only, and are in no way to be construed as part of this Agreement or as a limitation upon the scope of the particular section to which they refer. 
  

	1.3	Currency 

 Unless specified otherwise, all statements of or references to dollar amounts in this
Agreement are to lawful money of Canada. 
  

	1.4	Schedules 

 The following schedules form part of this Agreement: 

 

			
	Schedule A	  	Patent Applications
		
	Schedule B	  	Research Agreement
		
	Schedule C	  	Milestones
		
	Schedule D	  	University of Toronto Confidential Invention Disclosure

  
 Page 5 of 24 

 ARTICLE 2 

TECHNOLOGY LICENSE 
  

	2.1	Grant of License for Technology 

 Subject to the terms and conditions hereinafter set forth, UTIF hereby
grants to Licensee: 
  

	 	(a)	an exclusive license, within the Territory and within the Field of Use to develop, make, have made, use, sell, offer for sale and import Licensed Products under all Owners’ right, title and interest in the
Technology; and 

  

	 	(b)	an exclusive right to grant sub-licenses of all rights set out in Article 2.1(a) above provided that Licensee shall have the right to audit the books and records of each such sub-licensee in the same manner as UTIF as
per Section 3.3(f) hereof. Any such sub-licenses shall be subject to Section 7.2 (b) herein, and Licensee shall notify UTIF of any such sub-license at least thirty (30) days prior to its execution. Further, Licensee shall
promptly provide UTIF with a copy of each sub-license agreement entered into hereunder. 

  

	2.2	Reserved Rights 

 Licensee acknowledges that UTIF, on behalf of the Owners and the University, has
reserved a royalty-free, perpetual irrevocable license to use the Technology and Improvements for the purpose of research, education and administrative purposes. 
  

	2.3	Conversion to Non-Exclusive License 

 In the event that UTIF elects to convert the rights granted under
Section 2.1 herein to non-exclusive rights pursuant to Section 3.2(d) herein: 
  

	 	(a)	Licensee shall continue to pay all Third Party charges for the filing, prosecution and maintenance of the Patents pursuant to section 4.3 herein. 

 

	 	(b)	The right of Licensee to grant sub-licenses to a Third Party under subsection 2.1(b) herein shall be subject to the following conditions: 

 

	 	(i)	UTIF has not granted such Third Party with a non-exclusive license in relation to the Technology; 

  

	 	(ii)	UTIF is not in discussions/negotiations with such Third Party for a nonexclusive license in relation to the Technology; 

  

	 	(iii)	The prior written approval of UTIF, which approval shall not be unreasonably withheld; and 

  
 Page 6 of 24 

	 	(iv)	Licensee agrees to pay and shall pay to UTIF a non-refundable fee of five thousand dollars ($5,000) within ninety (90) days following the effective date of each sub-license. 

 

	 	(c)	Royalties and fees payable to UTIF pursuant to sections 2.3(b)(iv) and 3.l(a) herein shall be first applied to offset all reasonable expenses incurred by Licensee for filing, prosecuting, securing, and maintaining the
Patents subsequent to the date upon which the exclusive rights under section 2.1 herein are converted to non-exclusive rights (the “Conversion Date”). For further clarity, Licensee shall not be entitled to recover such expenses incurred by
Licensee prior to the Conversion Date. After Licensee recovers such expenses, any remaining royalties and fees shall be remitted to UTIF according to sections 2.3(b)(iv) and 3.1(a) herein. 

 

	 	(d)	All of the remaining terms and conditions of this Agreement shall continue to apply to Licensee. 

ARTICLE 3 
 CONSIDERATION

  

	3.1	Royalty 

  

	 	(a)	In consideration of the entering into of this Agreement, Licensee, together with all Affiliates, shall pay a royalty (the “Royalty Payment”) to UTIF of two and one-half percent (2.5%) of the Net
Sales made during the term of this Agreement. 

  

	 	(b)	If Licensee sub-licenses any rights under this Agreement to a Third Party, the Licensee shall pay UTIF a percentage of the upfront sub-license fees and any periodic milestone payments, sub-license maintenance fees,
sub-license milestone payments and similar non-royalty payments made by sub-licensees to Licensee on account of sub-licenses pursuant to this Agreement (the “Upfront Sub-License Fees”), if any such Upfront Sub-License Fees are paid
to Licensee, equal to: 

  

	 	(i)	fifty percent (50%) of the Upfront Sub-License Fees, if the sub-license occurs on or before September 9, 2005; 

  

	 	(ii)	twenty-five percent (25%) of the Upfront Sub-License Fees, if the sub-license occurs after September 9, 2005 but before September 9, 2006; or 

 

	 	(iii)	ten percent (10%) of the Upfront Sub-License Fees, if the sub-license occurs on or after September 9, 2006. 

  

	 	(c)	If Licensee sub-licenses any rights under this Agreement to a Third Party, the Licensee, on behalf of such sub-licensee, shall pay UTIF a royalty equal to two and one-half percent (2.5%) of the Net Sales in respect
of all sales of Licensed Products made during the term of this Agreement by the sub-licensee (the “Sub-License Royalty Payment”). 

  
 Page 7 of 24 

	 	(d)	The Upfront Sub-License Fees may include both cash and non-cash consideration as may be agreed upon between UTIF and Licensee. 

  

	 	(e)	If Licensee obtains rights to another royalty bearing technology which is included in the Licensed Products and the aggregate royalty payable on the Licensed Products by the Licensee to all parties is greater than five
percent (5%) of Net Sales, then Licensee may reduce the royalty payable to UTIF from two and one-half percent (2.5%) to one and one-half percent (1.5%) of Net Sales. In no case will the royalty payable to UTIF be less than one and
one-half percent (1.5%) of Net Sales. 

  

	3.2	Milestones 

  

	 	(a)	In relation to each Licensed Product, Licensee shall use reasonable commercial efforts to carry out those activities set out in Schedule C: Milestones hereto. 

 

	 	(b)	Upon First Commercial Sale of a Licensed Product, Licensee shall be deemed to have met all Milestones for that particular Licensed Product. 

 

	 	(c)	Subject to any applicable federal or provincial or state privacy laws or regulations, Licensee shall provide UTIF with the following reports within thirty (30) days following June 30th and December 31st of each year during the term of this Agreement: 

  

	 	(i)	a semi-annual development update disclosing a summary of research results (containing sufficient detail acceptable to UTIF, acting reasonably) obtained from the pre-clinical and clinical development of the Licensed
Product during the preceding six (6) month period; and 

  

	 	(ii)	a semi-annual updated business plan. 

 Said reports are expected to demonstrate continued
progress toward the Milestones and to ensure that Licensed Product opportunities and revenue potential is maximized. 
  

	 	(d)	If Licensee fails to either: 

  

	 	(i)	provide reports to UTIF pursuant to Section 3.2 (c) herein; or 

  

	 	(ii)	continue to make reasonable commercial efforts towards obtaining Regulatory Approval for a Licensed Product 

then Licensee shall cure such breach within six (6) months after written notice of such breach is given to Licensee by UTIF. In the event
that Licensee is unable to cure such breach within the said six (6) months, UTIF shall have the option to convert the rights granted pursuant to Section 2.1 herein to non-exclusive rights effective immediately. Upon First Commercial Sale
of a Licensed Product, this Subsection 3.2 (d) shall no longer apply for that particular Licensed Product. 

  
 Page 8 of 24 

	3.3	Accounting and Records 

  

	 	(a)	The Royalty Payments, the Upfront Sub-License Fees and the Sub-License Royalty Payments (collectively the “Fees”) under Section 3.1 herein are to be paid by Licensee to UTIF on a quarterly calendar basis
and shall be made within thirty (30) days after the end of each Calendar Quarter in which such Fees are received by Licensee. 

  

	 	(b)	The Parties acknowledge that the royalties and fees payable hereunder for all sales of Licensed Products within Canada are subject to the Canadian Goods and Services Tax (“GST”). Licensee hereby agrees to
provide UTIF a statement as to the Licensee’s GST status and to remit such amounts to UTIF as required under Canadian GST legislation. UTIF is registered to collect GST under registration number 10525 7117 RT000l. 

 

	 	(c)	Fees shall be paid to UTIF free and clear of all taxes including income taxes, except such taxes as the Licensee shall be required by law to withhold. 

 

	 	(d)	Licensed Products sold under the license granted herein, or under any sub-license, shall be deemed to have been sold when a Licensed Product is delivered and payment is received. 

 

	 	(e)	Licensee agrees to keep complete and accurate books of account in which the particulars of all sales of the Licensed Product are recorded in sufficient detail to enable Fees payable hereunder to be determined.

  

	 	(f)	UTIF, or their authorized representatives, shall have the right from time to time, upon ten (10) days prior written notice to Licensee, to audit Licensee’s said books and records of accounts and all of the
documents and other materials in the possession or under the control of Licensee with respect to the subject matter of this Agreement. UTIF reserves the right to confirm any information learned in the course of such audit with individuals or
corporations that have purchased a Licensed Product from Licensee to verify the accuracy of Licensee’s payments of Fees and compliance with the terms hereunder. Licensee shall preserve and keep available to UTIF all such books and records,
documents, contracts, and other data (including reports of audits undertaken by Licensee of the books and records of its own sub-licensees) with respect thereto for a period of six (6) years after the date of each such record.

  

	 	(g)	In the event that any audit of the books and records of Licensee reveals an error in excess of five percent (5%) to the detriment of UTIF, then Licensee shall bear all the costs of said examination and pay
forthwith all outstanding amounts together with interest thereon as set out under Subsection (i) hereof. 

  

	 	(h)	Each payment of the Fees hereunder shall be accompanied by a statement of the Net Sales certified correct by the chief financial officer of Licensee. 

  

  
 Page 9 of 24 

	 	(i)	Interest shall be payable on any amounts owed by one Party to another Party which are not paid when due, at the Prime Rate plus 3% per annum, compounded monthly. The payment of interest shall not be deemed an
alternative to the payment of amounts owing on the due dates, which payment shall be deemed to be in default, and if such default is not remedied within thirty (30) days of written notice thereof, UTIF may terminate this Agreement as provided
in Section 6.2. 

 ARTICLE 4 

INTELLECTUAL PROPERTY 
  

	4.1	Ownership 

 All Intellectual Property Rights in all aspects and parts of the Technology and Improvements
shall be exclusively owned by Owners, and/or David Lovejoy as the case may be, and nothing herein shall serve to, or should be construed to transfer any Intellectual Property Rights whatsoever in the Technology or Improvements. 

 

	4.2	Know-how 

 UTIF shall furnish a summary of the relevant Know-how to Licensee within a reasonable period
of time following the execution of this Agreement. 
  

	4.3	Patents and Patent Applications 

  

	 	(a)	UTIF, in the name of the Owners, or David Lovejoy as the case may be, as assignee, shall file, prosecute and maintain the Patents. Licensee, in consultation with UTIF, shall determine in which countries to pursue patent
applications. In the event that Licensee elects not to reimburse UTIF for the costs associated with a patent application in accordance with Section 4.3 (c) hereunder or to continue prosecution in any country, UTIF may, at its sole
discretion, file such patent or continue such prosecution in that country at its own expense. In such cases, any patents arising from such applications shall be excluded from the grant of rights under Section 2.1 herein and such country shall
be deleted from the definition of Territory herein. 

  

	 	(b)	Licensee acknowledges that prior to the Effective Date of this Agreement, UTIF has incurred out-of-pocket expenses in relation to the filing and prosecution of the Patents. Licensee shall reimburse UTIF for such
expenses (as evidenced by copies of invoices to be provided to Licensee) as follows: 

  

	 	(i)	Licensee shall pay UTIF ten thousand dollars ($10,000) within thirty (30) days following the Effective Date of this Agreement; and 

 

	 	(ii)	Licensee shall pay UTIF in consecutive installments of ten thousand dollars ($10,000) payable on a bi-monthly basis following the Effective Date of this Agreement until UTIF has been reimbursed in full.

  
 Page 10 of 24 

	 	(c)	Subject to Section 4.3(a) herein, all out-of-pocket filing, prosecution and maintenance expenses in relation to the Patents incurred following the Effective Date of this Agreement shall be at Licensee’s sole
expense. Without limiting the foregoing, Licensee shall pay UTIF any amounts anticipated to be payable or otherwise owing to any patent office in advance of when they would become due. 

 

	 	(d)	Subject to Sections 4.3(a) and 4.3(c) herein, the Parties hereto shall use reasonable commercial efforts to file patent applications in relation to STORM within two (2) years following the Effective Date of this
Agreement. In the event that patent applications are not filed within this period, Licensee shall have the option to file, prosecute and maintain patent applications in relation to STORM subject to the following conditions: 

 

	 	(i)	David Lovejoy will be named as the assignee on all such patent applications; 

  

	 	(ii)	All out-of-pocket filing, prosecution and maintenance expenses will be at Licensee’s sole expense; and 

  

	 	(iii)	Licensee will undertake to keep UTIF reasonably advised of the progress of prosecution and of any actions Licensee proposes to take in connection with the prosecution or maintenance of such patent applications, and
Licensee will diligently endeavor to provide UTIF with copies of correspondence and all actions issued by patent authorities. 

Provided that all of the conditions of this Section 4.3(d) have been satisfied, such patent applications in relation to STORM shall then
be included in the definition of Patents for purposes of this Agreement and licensed to Licensee under the terms of license granted hereunder. 
  

	 	(e)	UTIF undertakes to keep Licensee reasonably advised of the progress of prosecution and of any actions UTIF proposes to take or has taken in connection with the prosecution or maintenance of the Patents. UTIF shall
diligently endeavor to provide Licensee with copies of correspondence and all actions issued by patent authorities and shall take into account any comments, remarks or suggestions Licensee may promptly provide to UTIF in writing at least ten
(10) days prior to any due date established by UTIF for preparation of a response or amendment, and in all cases thirty (30) days prior to any patent office due date. 

 

	4.4	Improvements 

 UTIF shall inform Licensee promptly of any Improvements. Within one hundred and eighty
(180) days following the disclosure by UTIF of such Improvements, Licensee shall have the option to direct UTIF to file patent applications, in the name of the Owners, or David Lovejoy as the case may be, as assignee, in relation to the
Improvements provided that Licensee agrees to pay all expenses associated with the filing and prosecution of such patent applications. Subject to any rights of Third Parties and to the provisions of Section 4.3(a) herein, such applications
shall then be included in the definition of Patents for purposes of this Agreement and licensed to 

  
 Page 11 of 24 

 Licensee under the terms of license granted hereunder. If Licensee does not make its election within the one
hundred and eighty (180) days or if Licensee elects for UTIF not to file patent applications for such Improvements, UTIF shall have the right to apply for patents at its own expense, and any patents resulting from such applications shall be
excluded from the grant of rights under Section 2.1 herein. It is understood that Licensee shall not be obligated to undertake responsibility with respect to any such Improvements or developments unless it elects to do so. 

 

	4.5	Infringement 

  

	 	(a)	Each Party shall notify the other Party promptly of any actual or threatened infringement, limitation or unauthorized use of any Technology by a Third Party of which such Party becomes aware. 

 

	 	(b)	Licensee shall have the right, at its own expense to bring any claim, action or proceeding on account of any such infringements, limitations or unauthorized use of the Technology. UTIF agrees that it shall cooperate
with Licensee as Licensee may reasonably request in connection with any such claim, action or proceeding. Licensee agrees to reimburse UTIF for its reasonable expenses incurred in complying with any such request of Licensee. Any proceeds received by
Licensee from such claim, action or proceedings shall be first applied to offset Licensee’s litigation expenses. Any remaining proceeds shall then be distributed according to Section 3.1(a) herein. 

 

	 	(c)	If Licensee does not undertake to bring any such claim, action or proceeding on account of any such infringements, limitations or unauthorized use within thirty (30) days following the receipt of notice of such
infringement, limitation or unauthorized use, Licensee shall so notify UTIF and, at the expiry of such thirty (30) day period if the Licensee has not brought such claim, action or proceeding, UTIF may prosecute the same, at its expense.
Licensee agrees that if UTIF brings such a claim, action or proceeding, Licensee shall cooperate with UTIF, at UTIF’s expense, and UTIF shall be entitled to keep all the proceeds obtained from such claim, action or proceeding.

  

	 	(d)	Licensee shall have the right, at its expense, to defend and settle for other than money damages any claim, action or proceeding that may be commenced against Licensee or UTIF alleging that any Licensed Product
infringes any rights of others. UTIF may, at its option, participate in such claims, actions and proceedings through counselor as a party. Any settlement shall require the consent of UTIF. If Licensee does not defend or settle such claim, action or
proceeding, it shall notify UTIF of its election within thirty (30) days (or such shorter time period as may be required in order that UTIF may have reasonably sufficient time to comply with any statutory obligations for instituting such
defence) following the receipt of notice of same, and UTIF may defend same, at its expense. 

  
 Page 12 of 24 

	4.6	Confidentiality 

  

	 	(a)	All Confidential Information will remain the property of its owner or the Party that furnished it as the case may be. 

  

	 	(b)	Each Party agrees to maintain in confidence all Confidential Information disclosed with the same degree of care as it normally takes to preserve its own confidential information of similar grade, but in any event, no
less than a reasonable degree of care. 

  

	 	(c)	Each Party may only disclose Confidential Information to persons with a “need to know” who shall be made aware of, and be required to observe and comply with the covenants and obligations contained herein, and
the Confidential Information shall only be used to carry on or facilitate business as contemplated under this Agreement. 

  

	 	(d)	A Party may disclose Confidential Information pursuant to the requirements of a government agency or pursuant to a court order, provided that the Party shall take all reasonable steps, including, but not limited to the
seeking of an appropriate protective order, to preserve the confidentiality of the Confidential Information provided. 

  

	 	(e)	If this Agreement is terminated for any reason, any Party in receipt of Confidential Information shall promptly deliver or destroy all Confidential Information of the disclosing Party without retaining copies thereof,
except that the receiving Party may retain in the office of its legal counsel one (l) copy of written Confidential Information for record purposes only. 

  

	 	(f)	In the event that a Party becomes aware of, or perceives any threat that, any Confidential Information may be disclosed contrary to the provisions of this Section 4.6, or in the circumstances referred to in
Subsection 4.6(c), such Party shall immediately provide written notice thereof to the other Party. 

 ARTICLE 5 

REPRESENTATIONS, WARRANTIES AND INDEMNITY 
  

	5.1	Representations and Warranties of Parties 

 The representations of Licensee and UTIF, one to the other
are as follows: 
  

	 	(a)	Licensee is a corporation duly organized, validly existing and in good standing, and it has the right and authority to enter this Agreement, and do all acts and things as required or contemplated to be done, observed
and performed by them hereunder. 

  

	 	(b)	The execution, delivery and performance of this Agreement does not contravene any law, rule or regulation of either Party or of the jurisdiction in which it is incorporated. 

  
 Page 13 of 24 

	 	(c)	UTIF is a corporation duly organized, validly existing and in good standing, and it has the right and authority to enter this Agreement and the right to grant the license as provided herein and that such grant is not in
conflict with any other agreement to which it is a party. 

 EXCEPT FOR THE FOREGOING REPRESENTATIONS AND WARRANTIES PROVIDED IN THIS SECTION
5.1, UTIF DISCLAIMS ALL REPRESENTATIONS, WARRANTIES AND CONDITIONS OF ANY KIND, WHETHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING WITHOUT LIMITATION ALL REPRESENTATIONS, WARRANTIES AND CONDITIONS AS TO QUALITY, MERCHANTABLE QUALITY,
MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, SCOPE, PATENTABILITY, VALIDITY OR ENFORCEABILITY OF THE TECHNOLOGY OR THAT THE TECHNOLOGY IS SAFE FOR ANY USE OR PURPOSE WHATSOEVER, OR THAT THE TECHNOLOGY DOES NOT INFRINGE THE RIGHTS OF ANY
THIRD PARTY. 
  

	5.2	Indemnity 

 Licensee shall indemnify and hold harmless the Owners, their successors and assigns, and UTIF
and the University, including their parents, subsidiaries, affiliates, attorneys, agents, officers, directors, employees, administrators, predecessors, successors or assigns (collectively, the “Indemnities”) from and against any and
all claims, threats, loss, liability, damage or expense, including reasonable lawyers’ fees, by reason or arising out of any acts or failure to act by or out of any use of Technology, Patents or Licensed Products by sub-licensees or by Licensee
or their respective servants, agents, Affiliates, officers, directors, stock-holders, employees, or customers. The party seeking indemnification shall give the Licensee prompt notification of any such claim, threat, loss, liability, damage or
expense. The indemnity provided herein shall survive any termination or assignment of this Agreement without time limit. Licensee acknowledges that UTIF is entering this Agreement and obtaining for foregoing indemnification as agent for the other
Indemnities and is holding the rights contained in this paragraph in trust for the other Indemnities. 
  

	5.3	Insurance 

  

	 	(a)	Licensee, at its own expense and at all times, during the term of this Agreement and for the duration of its indemnity obligations which survive the expiration or premature termination of this Agreement pursuant to
Section 5.2 herein, shall carry and maintain in full force and effect comprehensive general liability insurance in amounts not less than $1,000,000 per incident and $2,000,000 annual aggregate, naming UTIF, the University and the Owners as
additional insureds. Prior to entering human clinical trials Licensee shall add product liability provisions, and Licensee shall increase the amounts of the insurance policy referred to hereinabove to $5,000,000 per incident and $5,000,000 annual
aggregate. 

  

	 	(b)	The coming into force of this Agreement is conditional upon UTIF having received a certificate of insurance from the insurance company, in a form acceptable to UTIF, within thirty (30) days following the Effective
Date. Such 

  
 Page 14 of 24 

	 	
policy shall contain an endorsement by the insurer providing that it shall not be reduced below the stated minimum, cancelled or amended without thirty (30) days prior notice to UTIF.
Licensee shall provide a certificate of such insurance to UTIF annually hereafter on the anniversary of the Effective Date. 

  

	5.4	Limitation of Liability 

 IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS DIRECTORS, OFFICERS, CONTRACTORS,
EMPLOYEES OR AGENTS BE LIABLE FOR ANY INDIRECT, SPECIAL, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR EXEMPLARY DAMAGES OR EXPENSES OF ANY TYPE (INCLUDING BUT NOT LIMITED TO ANY DAMAGES FOR LOST PROFITS, LOSS OF USE, BUSINESS INTERRUPTION, LOSS OF DATA,
LOST BUSINESS OR LOST SAVINGS) ARISING OUT OF THIS AGREEMENT OR THE TECHNOLOGY, WHETHER SUCH DAMAGES OR EXPENSES ARISE OUT OF BREACH OF CONTRACT (INCLUDING FUNDAMENTAL BREACH), OR TORT OR ON ANY OTHER STATUTORY OR COMMON LAW BASIS, EVEN IF THAT
PARTY OR ANY OF ITS DIRECTORS, OFFICERS, CONTRACTORS, EMPLOYEES OR AGENTS HAS BEEN ADVISED OF THE POSSIBLITY OF SUCH DAMAGES. 
 ARTICLE 6

 TERM AND TERMINATION 
  

	6.1	Term 

 This Agreement shall come into effect upon the Effective Date, and unless earlier terminated,
shall terminate on the expiration or invalidity of the last issued Patent. 
  

	6.2	Termination 

  

	 	(a)	The occurrence of anyone or more of the following events shall constitute an event of termination of this Agreement and shall, in addition to any other right or remedy either Party may have, permit a Party hereto to
immediately terminate this Agreement: 

  

	 	(i)	if the other Party breaches any material covenant or obligation in this Agreement, other than a breach of the Milestones as specified in section 3.2 herein, and such breach is not fully remedied within thirty
(30) days after the Party in breach receives written notice of such breach from the other Party; or 

  

	 	(ii)	if Licensee fails to provide UTIF with a certificate of insurance pursuant to Section 5.3 (b) herein; or 

  

	 	(iii)	in the event of any adjudication of bankruptcy, appointment of a receiver by a Court of competent jurisdiction, assignment for the benefit of creditors, involving the other Party either voluntary or involuntary, or
appointment of a receiver by the other Party for any reason whatsoever. Such termination shall not impair or prejudice any other right or remedy that UTIF may otherwise have under this Agreement. 

  
 Page 15 of 24 

	 	(b)	Licensee may, at its sole discretion, terminate this Agreement upon thirty (30) days prior written notice to UTIF in the event that UTIF elects to make this license non-exclusive pursuant to Section 3.2
(d) herein. 

  

	 	(c)	UTIF may, at its sole discretion, terminate this Agreement upon thirty (30) days prior written notice to Licensee in the event that Licensee does not Secure a minimum of two hundred and forty-seven thousand and two
hundred dollars ($247,200) within six (6) months following the Effective Date of this Agreement. 

  

	 	(d)	Termination as set forth in this Section shall not relieve any of the Parties of any obligations accrued under this Agreement prior to the date of termination. The following provisions shall survive termination of this
license: Sections 3.3 (Accounting & Records); 4.1 (Ownership); 4.6 (Confidentiality); 5.2 (Indemnity); 5.3 (Insurance); 5.4 (Limitation of Liability); 6 (Termination and Effect of Termination); and 7 (General Provisions). 

 

	6.3	Effect of Termination 

 Upon termination of this Agreement, Licensee shall forthwith: 

 

	 	(a)	cease use of Technology and Licensed Products; 

  

	 	(b)	pay promptly all amounts it owes to UTIF; 

  

	 	(c)	assign any and all sub-licenses granted under this Agreement to UTIF; and 

  

	 	(d)	subject to Section 4.6 (e) herein, return to UTIF all Confidential Information. 

ARTICLE 7 
 GENERAL

  

	7.1	Time 

 Time is of the essence of each provision of this Agreement. 

 

	7.2	Assignment and Sub-licenses 

  

	 	(a)	Neither Party may sell, assign, encumber, license or otherwise transfer any of its rights, duties or obligations hereunder without the prior written consent of the other Party, which consent shall not be unreasonably
withheld. Notwithstanding the foregoing, either Party may assign its rights and obligations hereunder to a entity acquiring all, or substantially all of such Party’s business or assets without the prior consent of the other Party.

  
 Page 16 of 24 

	 	(b)	The Licensee is responsible for any and all activities of any sub-licensee and the sub-licensee shall adhere to all confidentiality, indemnity and insurance requirements set forth in this Agreement. No sub-license
granted by Licensee shall be less favorable with respect to any term or condition to UTIF than the license granted herein. 

  

	7.3	Notices 

 Any notice, demand or other communication required or permitted to be given or made hereunder
shall be in writing and shall be sufficiently given or made if delivered personally or sent by prepaid registered mail to its address or by telecopier to the number and to the attention of the person set forth below: 

 

	 	(a)	In the case of a notice to Licensee: 

 Protagenic Therapeutics, Inc. 

4264 Corte Favor, 
 San Diego,
California, 
 92130 

Attention: President 
 Telecopier
No.: (•) • 
 With a copy to: 

John D. Tishler 
 Sheppard
Mullin Richter & Hampton LLP 
 12544 High Bluff Drive, Suite 300 

San Diego, CA 92130 
 Telecopier
No.: (858) 509-3691 
  

	 	(b)	In the case of a notice to UTIF: 

 University of Toronto Innovations Foundation 

243 College Street, Suite 200 

Toronto, Ontario 
 M5T lR5 

Canada 
 Attention: Executive
Director 
 Telecopier No: (416) 978-6052 

Each notice sent in accordance with this Section shall be deemed to have been given and received: 

  
 Page 17 of 24 

	 	(i)	if delivered, on the day it was delivered if received within normal business hours; 

  

	 	(ii)	if mailed, on the fifth business day following the date on which it was mailed, unless an interruption of postal services occurs or is continuing on or within the five business days after the date of mailings in which
case the notice shall be deemed to have been received on the fifth business day after postal service resumes; 

  

	 	(iii)	if sent by telecopier, on the day it was received, or on the first business day thereafter if the day on which it was sent was not a business day or outside normal business hours. 

Either Party may by notice to the other, given as aforesaid, designate a changed address or telecopier number. 

 

	7.4	Conflict 

 In the event any term or any part of any term of this Agreement is determined to be void or
unenforceable, such term or part of a term shall be considered separate and severable from this Agreement and the remaining terms shall continue in full force and effect. 
  

	7.5	Governing Law & Attornment 

 This Agreement shall be interpreted and construed in accordance
with the laws of the Province of Ontario and the laws of Canada applicable therein, and each Party hereby attorns and submits to the non-exclusive jurisdiction of the courts of the Province of Ontario, Canada. 

 

	7.6	Further Assurances 

 The Parties agree to execute, acknowledge and deliver all such further instruments,
and to do all such other acts, as may be necessary or appropriate to carry out the intent and purpose of this Agreement. 
  

	7.7	Waiver of Rights 

 The failure of a Party at any time to request the other Party hereto to comply with
any of the terms, conditions or covenants hereof shall not be deemed a waiver of such terms, conditions or covenants. Waiver by a Party of a breach of any term or condition of this Agreement shall not be considered a waiver of any subsequent breach
of the same or of any other term or condition hereof. 
  

	7.8	Relationship of the Parties 

  

	 	(a)	The relationship of Licensee to UTIF is that of an independent contractor and neither Licensee nor its agents or employees shall be considered employees of UTIF. This Agreement does not constitute and shall not be
construed as constituting a partnership or joint venture or grant of a franchise between Licensee and UTIF. 

  
 Page 18 of 24 

	 	(b)	A Party will not use the name of any other Party, nor any member of such Party’s staff in any advertising or publicity without the prior written approval of an authorized representative of the body whose name is to
be used. However, a Party may notify others of the fact that this Agreement is in effect. 

  

	7.9	Force Majeure 

 No Party shall be liable to any other party for delay or failure in the performance of
any of its obligations hereunder if such failure is caused by Force Majeure, as hereinafter defined. For the purposes hereof, “Force Majeure” means any act of God, action or failure to act of any government or governmental or
regulatory authority, failure of supplies, materials, equipment, labour or transportation being provided by any other person, power failure or shortage, strike, lockout, work slowdown or stoppage, accident, fire, flood, explosion, storm, other
natural occurrence, sabotage or other event beyond the control of the relevant party. 
  

	7.10	Rights and Remedies 

 In the event that there is a dispute regarding any covenant or obligation in this
Agreement, a Party shall be entitled to exercise any right or remedy available to it at law. Such rights shall include, without limitation, termination of this Agreement, and damages. 

 

	7.11	Entire Agreement 

 This Agreement, including all attached Schedules which are hereby incorporated by
reference, sets forth the entire agreement and understanding of the Parties relating to the subject matter contained herein and merges all prior discussions and agreements between them, and neither Party shall be bound by any definition, condition,
warranty or representation other than expressly stated in this Agreement. Any amendment to this Agreement shall not be effective unless it is in writing and signed by the duly authorized signing officers of each Party. 

 

	7.12	Facsimile Execution 

 To evidence the fact that it has executed this Agreement, a Party may send a copy
of its executed counterpart to the other Party by facsimile transmission. That Party shall be deemed to have executed this Agreement on the date it sent such facsimile transmission. In such event, such Party shall forthwith deliver to the other
Party the counterpart of this Agreement executed by such Party. 

  
 Page 19 of 24 

	7.13	Succession 

 This Agreement shall be binding upon and enure to the benefit of the Parties hereto and
their respective successors and assigns. 
 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed in a legally binding manner.

 UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION 
  

			
	Per:	 	 /s/ Ron Venter

		 	Ron Venter, Ph.D.
		 	Interim-Executive Director
	
	PROTAGENIC THERAPEUTICS, INC.
		
	Per:	 	 /s/ Haro Hartounian

		 	Haro Hartounian
		 	Assistant Secretary

  
 Page 20 of 24 

 Schedule A 

Patent Applications 
  

			
		
	Application No.:	  	PCT /CA03/00622
		
	Title:	  	“Teneurin C-Terminal Associated Peptides (TCAP) and Methods and Uses Thereof”
		
	Inventors:	  	David Lovejoy, Bradley Chewpoy, Dalia Barsyte and Susan Rotzinger
		
	Filed:	  	May 2, 2003

  
 Page 21 of 24 

 Schedule B 

Research Agreement 

  
 Page 22 of 24 

 This RESEARCH AGREEMENT (the “Agreement”) is made and entered into as of December 14, 2004
(the “Effective Date”) by and between: 
 PROTAGENIC THERAPEUTICS, INC. 

(the “Company”) 
 –
and – 
 THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO 

(the “University”) 
 WHEREAS, Professor
David Lovejoy (“Dr. Lovejoy”) of the University of Toronto, Department of Zoology, has invented a proprietary genetic algorithm known as “STORM” for finding and predicting function(s) of novel therapeutic peptides that may be
mimicked by small molecules, one such example of peptide is currently subject of the PCT patent application number PCT/CA03/0062 entitled “TENEURIN C-TERMINAL ASSOCIATED PEPTIDES (TCAP) AND METHODS AND USES THEREOF” (the
“Technology”); 
 WHEREAS, Dr. Lovejoy has entered into an agreement with the University of Toronto Innovations Foundation (“UTIF”)
in order to commercialize the Technology; 
 WHEREAS, UTIF entered into a Memorandum of Understanding (“MOU”) with the Company that outlines a
plan for commercialization; 
 WHEREAS, a condition of the MOU is that the Company must enter into a licence agreement with UTIF for the Technology (the
“License Agreement”), and a research agreement with the University to further develop the Technology, both agreements to be upon the terms set forth in the MOU. 

WHEREAS, the University is prepared to undertake a research project entitled “[[Project Title]]” (the “Project”); 

AND WHEREAS, the Company wishes to support the Project. 
 The
Company and the University hereby agree as follows: 
  

	1.	Project. The University and the Principal Investigator (as defined below) shall perform the Project in accordance with this Agreement and the research plan set forth in Appendix A, as may be amended from time to
time by mutual agreement of the parties in accordance with this Section 1 and Section 3 (the “Research Plan”). The initial Research Plan shall encompass the first six months ($52,800) of the Project. Prior to receipt of the second
payment ($194,400) the Principal Investigator will be required to submit a revised Research Plan to the Company for its approval. Once the Company has approved the revised Research Plan, the Research Plan will be amended to reflect such revisions.
At any time during the Term, the parties may amend the Research Plan upon mutual written agreement. 

  

	2.	Term. The initial term of this Agreement shall commence upon the Effective Date and will end on the second (2nd) anniversary of the Effective Date, unless terminated earlier pursuant to Section 14 (the
“Term”). The Term may be extended upon mutual agreement of the parties to include additional research beyond such initial two (2) year period. 

  

	3.	Principal Investigator. The “Principal Investigator” for the Project shall be Dr. David Lovejoy. The Principal Investigator shall be responsible for the technical content of the Project and
overseeing and managing the Project. So long as Dr. Lovejoy is an employee of the University and is willing to be the Principal Investigator, the University will maintain Dr. Lovejoy as the Principal Investigator; provided, however, that
if Dr. Lovejoy becomes unavailable at any time during the Project, the University may nominate a replacement Principal Investigator, such nomination to be made within fourteen (14) days of the date on which Dr. Lovejoy becomes
unavailable. If the Company, for any reason, does not accept the replacement Principal Investigator or a replacement Principal Investigator is not nominated by the University, the Research Plan may be amended to reflect a reduced scope of work for
the Project, or the Agreement may be terminated by the Company as set forth in Section 14. 

  
 -1- 

	4.	Undertakings. 

 (a) The University shall ensure that, prior to the commencement of the
Project: (i) the Principal Investigator shall execute the Principal Investigator’s Undertaking (“PIU’,) attached hereto as Appendix C; (ii) any additional personnel, including without limitation, each additional
investigator, involved in the Project (the “Personnel”) shall execute a Confidential Information and Intellectual Property Agreement (“CIIP”) substantially in the form attached hereto as Appendix D; and (iii) in the event
that Dr. Lovejoy is replaced in accordance with Section 4 with a replacement Principal Investigator, the new Principal Investigator shall execute a PIU and each existing and new Personnel shall execute a CIIP under the replacement
Principal Investigator. 
 (b) The University and Principal Investigator shall ensure that all work performed by such personnel on the
Project is in compliance with the terms of this Agreement. 
  

	5.	Budget. In consideration of the University carrying out the Project, the Company shall pay the University the sum of CDN $247,200 and certain additional compensation all in accordance with the budget and payment
schedule attached as Appendix B. 

  

	6.	Payment. All cash payments shall be made by cheque payable to the University of Toronto and addressed to the Assistant Vice-President, Technology Transfer. The First Instalment (as defined in Appendix B) will be
paid upon execution of this Agreement and the Second Instalment (as defined in Appendix B) shalt be paid upon the last to occur of the following: (i) February 31, 2005; (ii) the date which is two (2) months from the final
execution of the Research Agreement; or (iii) the date which is two (2) months from the final execution of the Licence Agreement. 

  

	7.	Equipment. The University will own any equipment or material purchased by or provided to the University as part of the Project. 

 

	8.	Meetings and Reports. 

 (a) The University through the Principal Investigator, the other
investigators and any other appropriate Personnel will participate in bi-weekly telephone conversations, and at the discretion of the Company, monthly in-person meetings. Representatives of the Company shall be entitled to participate in such
meetings. 
 (b) The University shall share all data, research work conclusions and recommendations arising from the performance of the
Project (“Research Results”) with the Company, and shall provide reports regarding all Research Results as follows: (i) quarterly written reports, and more frequently upon specific request from the Company, presenting a meaningful
summary of the research accomplished and comparing Research Results to the Research Plan, including without limitation, costs incurred with a comparison to Appendix B; and (ii) a fmal report within sixty (60) days after the end of the
Term, or in the event the Term is extended, upon the end of such extended term. 
 (c) The Company shall have the right to use the Research
Results and the reports (i) in connection with the research, development and commercialization of the Company’s future products; (ii) to promote the Company; and (iii) as required for any regulatory submission or other submission
to a government authority. 
  

	9.	Confidential Information. Each of the parties may disclose confidential information (the “Disclosing Party”) to the other party (the “Receiving Party”) to facilitate work under this Agreement.
Such information (“Confidential Information’’) shall be so identified in writing at the time of its transmittal to the Receiving Party, or so reduced to writing within ten (10) days thereafter. Confidential Information shall be
maintained and held in strict confidence by the Receiving Party using the same methods and to the same degree of care (but at least reasonable care) that the Receiving Party uses to prevent disclosure of its own Confidential Information and shall
not be 

  
 -2- 

 
disclosed to third parties by the Receiving Party without the written consent of the Disclosing Party; provided, however, that the Receiving Party may disclose the Disclosing Party’s
Confidential Information to its agents, employees, officers, trustees, directors and representatives on a need-to-know basis (including, fulfilling corporate reporting obligations), as necessary to complete the Project in accordance with this
Agreement, and only if the foregoing parties are bound in writing to be obligated by the same provisions of confidentiality and non-use with respect to such Confidential Information as are set forth herein. Confidential Information shall only be
used by the Receiving Party for the purposes set forth in this Agreement, the MOU and the License Agreement. Confidential Information shall not include information that the Receiving Party can show by competent written evidence: 

 

	 	(a)	is already known to the Receiving Party without any obligations of confidentiality; 

  

	 	(b)	is or becomes part of the public domain without breach of this Agreement; or, 

  

	 	(c)	is obtained from a third party who has no obligations of confidentiality to the parties to this Agreement. 

Notwithstanding the above, the Receiving Party may disclose Confidential Information, without violating the obligations of this
Agreement, to the extent the disclosure is required by a valid court order or other governmental body having jurisdiction; provided that the Receiving Party gives reasonable prior written notice to the Disclosing Party of such required disclosure
and makes a reasonable effort to obtain, or to assist the Disclosing Party in obtaining, a protective order preventing or limiting the disclosure and/or requiring that the Confidential Information so disclosed be used only for the purposes for which
the law or regulation requires, or for which the order was issued. 
  

	10.	Intellectual Property. Any new intellectual property, including without limitation, technical information, know-how, copyrights, models, drawings, specifications, prototypes, inventions, improvements,
discoveries, or software developed in performance of the Project (“Intellectual Property”) will be owned by the University. In accordance with the terms of the MOU, or following execution of the License Agreement, in accordance with the
terms of the License Agreement, the Company shall have the option to exclusively license with rights of sub-license the Intellectual Property on the same royalty, sublicense fee and other terms as set forth in the MOU with respect to the licensing
of the Technology to the Company. The option will be for one hundred eighty (180) days after disclosure of the Intellectual Property to the Company, and the license fee for such Intellectual Property, if the option is exercised, shall be equal
to the out-of-pocket patent prosecution costs that the University, or its designate, has incurred with respect to such Intellectual Property prior to the exercise of such option. The Principal Investigator and all other Personnel are required to
disclose all Intellectual Property to the University and any such disclosure shall also be made to the Company. The University, the Principal Investigator and all other Personnel shall execute all documents necessary and sufficient to enable the
licensing of the Intellectual Property to the Company. The University reserves the non-transferrable, non-assignable, non-sublicenseable right to use the Intellectual Property for research, teaching and other administrative purposes upon terms to be
more fully described in the License Agreement. 

  

	11.	Publications. The University may publish or disclose the Research Results as permitted under this Section 11. Each such publication shall be authored as is scientifically appropriate and shall acknowledge
the support of the Company in all such publications. The University will provide a copy of any proposed publication or disclosure to the Company for its review at least thirty (30) days before submission for publication or disclosure. Upon the
Company’s written request received within twenty (20) days of the Company’s receipt of a copy of such publication or disclosure, the University will, at the Company’s option: 

 

	 	(a)	delay publication up to sixty (60) additional days to enable the Company to secure intellectual property protection of Intellectual Property that would be publicly disclosed by said publication; and/or,

  
 -3- 

	 	(b)	delete any Confidential Information provided by Company from the manuscript or proposed disclosure. 

Prior to the earlier of completion of the First Research Milestone or termination of this Agreement, all publications or disclosures shall be
made only upon the mutual agreement of the parties. For purposes of this Agreement, “First Research Milestone” shall mean identification of a single lead compound candidate ready for commencement of pre-clinical investigations. 

 

	12.	Indemnity. The Company shall indemnify, defend and hold harmless the University and its trustees, officers, directors, employees and agents from and against all claims, demands, suits or actions by third parties
for any liability, loss, damage or cost (“Losses”) arising out of injuries (including death) to persons participating in the Project or damage to property, caused by agents or personnel of the Company during the performance of this
Agreement, except to the extent such Losses are attributable to the wilful or negligent act or omission of personnel or agents of the University. The University shall indemnify, defend and hold harmless the Company and its directors, officers,
employees and agents from and against all Losses arising from injuries (including death) to persons participating in the Project or damage to University property caused by the wilful or negligent act or omission of personnel or agents of the
University during the performance of this Agreement, except to the extent such Losses are attributable to the wilful or negligent act or omission of personnel or agents of the Company. The party seeking indemnity under this Section 12 shall
promptly and in any event within thirty (30) days notify the indemnifying party of any known complaint, claim or injury which is the subject of a Loss by such indemnified party. The indemnified party shall, and shall ensure that any fellow
indemnitees, cooperate with the indemnifying party in the defense or settlement of any claim of Loss under this Section 12; provided, however, that no indemnitee shall be required to admit fault or responsibility in connection with any
settlement. The indemnified party shall have the right to select and to obtain representation by separate legal counsel at such indemnified party’s own expense. 

 

	13.	Representations and Warranties; Limitation of Liability. 

  

	 	(a)	Each party represents and warrants that the terms of this Agreement are not inconsistent with its other contractual arrangements or obligations. 

 

	 	(b)	Each party represents and warrants that (i) it has the full power and authority to enter into this Agreement, (ii) this Agreement has been duly authorized, and (iii) this Agreement is binding upon it.

  

	 	(c)	The University shall not be liable for any delays in the performance of its obligations under this Agreement resulting from circumstances or causes beyond the University’s control, and in no case shall the
University be liable for loss of business or profit or other indirect or consequential damage. 

  

	14.	Termination. This Agreement may be terminated as follows: 

  

	 	(a)	by the University upon giving sixty (60) days written notice to the Company, if, in the reasonable judgement of the Principal Investigator, the research program is no longer technically feasible; 

 

	 	(b)	by the Company upon giving sixty (60) days written notice to the University if, in the reasonable judgement of the Company, the research program is no longer technically or commercially feasible; 

 

	 	(c)	by the Company upon giving thirty (30) days written notice to the University if, at any time during the Term or any extension thereof, the parties are unable to agree on the terms of an amendment to the Research
Plan; 

  

	 	(d)	by the Company immediately upon giving written notice to the University if (i) the Company does not accept the replacement Principal Investigator nominated by the University or (ii) if no replacement Principal
Investigator is nominated by the University within fourteen (14) days of the date on which Or. Lovejoy becomes unavailable; 

  
 -4- 

  

	 	(e)	by the Company upon giving thirty (30) days written notice to the University if a research milestone has not been achieved within the time period specified in the Research Plan; or, 

 

	 	(f)	by either party upon giving thirty (30) days written notice to the other if the other party is in default of fulfilling any of its obligations under this Agreement and such default has not been cured within such
thirty (30) days notice period. 

 Upon termination, the University will be entitled to credit for work performed
hereunder prior to such termination, including all non-cancellable costs incurred by the University prior to the date of notice of termination, and the Company will be entitled to a return of the remaining balance of any advance payment. The
University shall use reasonable efforts, and shall ensure that the Principal Investigator uses reasonable efforts, to minimize the non-cancellable costs and expenses associated with the termination of the Agreement. Upon termination, the Company
may, in its sole discretion, pursue research under the Research Plan beyond the First Research Milestone outside of this Agreement. Expiration or termination of this Agreement will not relieve the parties of any obligation accruing prior to such
expiration or termination. Sections 5, 6, 8, 9, 10, 11, 12, 13(c), 14, 15, 16, 17, 18, 19, 20 and 21 will survive termination of this Agreement. 
  

	15.	No Use of Names. Neither party win use the name of the other party, or of any member of the other party’s personnel, in any advertising or publicity without the prior written approval of the other
party’s authorized representative. However, both parties may make the following information a matter of public record: name of the Principal Investigator; the Principal Investigator’s department; the University’s name; the
Company’s name; the Project title; and the Project duration. 

  

	16.	Notices. Notices under this Agreement will be sent to the appropriate party at the address specified below, with copies to the additional addresses for such party specified below, or at such other address(es) as
the party shall specify in writing: 

  

	 	(a)	to the University: 

  

	 	i.	for technical and scientific matters: 

 Professor David Lovejoy 

Department of Zoology 
 Faculty
of Arts and Science 
 25 Harbord Street, RW305 

Toronto, Ontario, M5S 3G5 
 

: 416-946-7259 
  

	 	ii.	for legal and administrative matters: 

 Peter B. Munsche 

Assistant Vice-President, Technology Transfer 

University of Toronto Research Services 

27 King’s College Circle 

Toronto, Ontario M5S 1A1 
 

: 416- 978-6063 /

: 416-978-5821 

	 	(b)	to Company: 

  

	 	i.	for scientific and technical matters: 

 Protagenic Therapeutics, Inc. 

Attn: Chief Scientific Officer 

4264 Corte Favor 
 San Diego, CA
92103 

  
 -5- 

 

:            /

:             
  

	 	ii.	for legal and administrative matters: 

 Protagenic Therapeutics, Inc. 

Attn: Chief Operating Officer 

4264 Corte Favor 
 San Diego, CA
92103 
 

:            /

:             
  

	 	iii.	with a copy to: 

 John D. Tishler 

Sheppard Mullin Richter & Hampton LLP 

12544 High Bluff Drive, Suite 300 

San Diego, CA 92130 
 

: 858-720-8900 /

: 858-509-3691 
  

	17.	Independent Parties. The parties are independent parties and nothing in this Agreement shall constitute either party as the employer, principal or partner of or joint venturer with the other party. Neither party
has any authority to assume or create any obligation or liability, either express or implied, on behalf of the other. 

  

	18.	No Assignment. Neither party may sell, assign, encumber, licence or otherwise transfer any of its rights, duties or obligations under this Agreement without the prior written consent of the other party, which
consent may not be unreasonably withheld. Notwithstanding the foregoing, the Company may assign its rights or obligation to an entity acquiring all, or substantially all of the Company’s business or assets without obtaining the consent of the
University. 

  

	19.	Successors. This Agreement shall binding and enure to the benefit of the parties and their respective heirs, successors and assigns. 

 

	20.	Governing Law. This Agreement shall be governed by and construed in accordance with the laws of Canada and the laws of the Province of Ontario applicable therein. 

 

	21.	Entire Agreement. This Agreement is the entire agreement of the parties and no change or modification shall be valid unless it is in writing and signed by both parties. 

In witness whereof the parties agree to be bound by the terms of this Agreement. 
  

							
	 THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
	  	 PROTAGENIC THERAPEUTICS, INC.

		
	 /s/ Peter Munsche
	  	 /s/ H. Hartounian

	Name:	 	Peter Munsche	  	Name:	  	H. Hartounian
	Title:	 	Vice-President, Technology	  	Title:	  	Chairman
		 	Transfer	  		  	

  
 -6- 

 PRINCIPAL INVESTIGATOR: 

I, the Principal Investigator, having read this Agreement, hereby agree to act in accordance with all the terms and conditions herein and further to agree to
ensure that all University participants are informed of their obligations under such terms and conditions. 
  

	
	 /s/ David Lovejoy

	 Professor David Lovejoy, University of Toronto, Department of Zoology

  
 -7- 

 APPENDIX” A” 

Research Plan 
 Dr. D.A.
Lovejoy: Research Plan 
 for Protagenic Therapeutics, Inc. 

Phase I Funding 
 Time Scale: 6 months from onset of
funding 
 PROJECT TITLE: Evidence for existence of TCAP receptors in neurons. 

GOALS: 
  

	1)	Determination of the most appropriate cell line to evaluate TCAP ligand affinity for its receptor. 

  

	2)	Determination of cell lines that do not have TCAP receptors 

  

	3)	Determination of the most appropriate cell line in which to purify the TCAP receptor 

 Background: The
identification of eventual structural characterization of high affinity TCAP receptors are essential to develop a high sensitivity ligand-screening assay for the purpose of evaluating future TCAP peptide variants and ultimately as a high-throughput
testing platform to develop TCAP small molecule mimics. We have a unique advantage to develop a distinct receptor-screening assay by capitalizing on the use of the recently developed immortalized hypothalamic cell lines. We have screened these
cells for TCAP responsiveness and identified four cell lines that are responsive to TCAP as determined by cAMP modulation abilities. However, we have determined that cAMP is not a reliable endpoint as an evalution method. Many hormones can trigger
an increase in cAMP in some parts of the cell, for example neurites and axon hillock regions, but a decrease in dentrites. Thus using a monoculture of cells can lead to inconsistent results depending upon the confluency, passage and growth rate of
the cultured cells. Ligand-binding determinations are a more reliable determination as a first level of evalution of ligand activity because receptor activation is a prerequisite for downstream cellular activity such as cAMP. 

Experimental Design: Plasma membrane preparations of four different mouse neuronal cell line cultures will be used to measure the affinity of mouse
TCAP-l for the endogenous receptor. Cells will be grown initially to 50 to 60% confluency, as we have previously determined that this cell density is the most consistent in terms of TCAP action using neurite outgrowth and cAMP as physiological
endpoints. Receptor affinity will be evaluated using two methods: 1) Scintillation proximity assays (SPA) and 2) radioreceptor assays. The scintillation assay has the advantage in that it is already designed to be a high throughput method. It has
the disadvantage in that it has a lower sensitivity than other methods, and so the optimization of the cell type and receptor expression level are key requirements for an effective method. We have used this method in the past with ectopically
expressed receptors in a rapidly growing cell line. The radioreceptor assay, on the other hand is highly sensitive and specific using a radiolabelled TCAP ligand. We have used this method in the past to evaluate small sequence changes in peptides
with a similar structure to TCAP. The disadvantage of this method is that it cannot be readily scaled up to a high-throughput level. Thus for the purposes of defining the level of TCAP receptor expression and its affinity for its ligand, both
methods are complementary. 

  
 -8- 

 Goal 1: Determination of the most appropriate cell line to evaluate TCAP ligand
affinity for its receptor. 
 TCAP affinity determined by as strong response using the SPA assay, and confirmed by the radioreceptor
assay will be selected as the cell line for high throughput screening 
 Goal 2: Determination of cell lines that do not have
TCAP receptors. 
 A negative response in the form of a flat displacement curve for both assays will be used as evidence that the
TCAP receptor is not present. As further confirmation of this, a cAMP assay will be employed. 
 Goal 3: Determination of the
most appropriate cell line in which to purify the TCAP receptor 
 Cell lines showing a strong affinity curve with a single binding
site will be selected to for the purification of the receptor. Proteins with affinity for TCAP will be examined using ligand photoaffinity crosslinking to the bound protein. 

Challenges and Interpretation: Although we already possess cell lines with the TCAP receptor that can yield a measurable response, high levels of
receptor expression are essential for a sensitive screening assay. Endogenously expressed receptors may not be expressed at a level that is viable for a screening assay that can be scaled up to a high-throughput type level. In this case, it may be
necessary to explore additional heterologous systems where the TCAP receptor is ectopically expressed in for example non-neural cells using a vector system incorporating a high expression promotor (e.g. CMV). We have utilized a similar system in the
past to evaluate novel peptide designs and, therefore, have the experience to develop this further, if necessary. Our preliminary investigations also indicate that the affinity of the TCAP receptor may be altered by the presence of GPCR-modulating
proteins, particularly the RAMP proteins. Thus, if using a heterologous expression system, the appropriate RAMP may have to be coexpressed. Alternatively, if receptor levels are of sufficiently high levels in the homologous neuronal systems, then
using the appropriate cell line with the requisite accessory proteins will be essential. 
 Timelines 

The setting up and optimization of the receptor assay systems are expected to take about 2 months. Determination of the appropriate cell lines are expected to
take 2-4 months depending of the data obtained. Within this period we will know whether an endogenously expressed receptor system or an ectopically expressed receptor system is more sensitive to evaluate the compounds. About 2 to 4 months will be
required to evaluate the levels of TCAP bound protein in the responsive cell lines. A number of the project goals can be done in parallel to each other such that about 6 months will be required to answer these questions. 

Personnel: An entry-level post-doctoral scientist with a background in molecular pharmacology will be responsible for the setting up and optimization
of the assay, as well as the analysis of the peptide binding curves. This individual will also be responsible for organizing the testing regimens and in consultation with Dr. Lovejoy making the decision on the appropriate cell lines and
preparing the data reports. A junior research assistant is will be required for the preparation and maintenance of the cell lines as well as assist as necessary in the preparation of the cell and membrane extracts. The scientist in training, Arij Al
Chawaf, presently a Ph.D student in Dr. Lovejoy’s laboratory, who has been developing the receptor characterization assays will evaluate the cell lines selected for the purification of the receptor using photoaffinity crosslinking
purification. 

  
 -9- 

 Phase / Budget: Evalution of TCAP receptor affinity in immortalized neurons 

 

							
	 Personnel
	  	Post Doctoral Scientist	  	 	21,000	  
		  	Research Assistant	  	 	12,500	  
		  	Scientist in training	  	 	2,000	  
		  	total	  	 	35,500	  
			
	 Consumables
	  	SPA kits	  	 	7,000	  
		  	Radioisotopes	  	 	2,500	  
		  	disposable labware	  	 	800	  
		  	chemicals	  	 	500	  
		  	Electrophoresis	  	 	5500	  
		  	Tissue culture	  	 	1000	  
			
		  	total	  	 	17,300	  
			
		  	grand total	  	 	52,800	  

  

  
 -10- 

 APPENDIX “B” 

Budget 
 Cash Payment 

 

									
	 	  	First Installment	 	  	Second Installment	 
	 Direct Costs
	  	CDN$	45,913	  	  	CDN$	169,043	  
	 O/H Cash
	  	CDN$	6,887	  	  	CDN$	25,357	  
		  	  
	  
	 	  	  
	  
	 
	 Total Cash
	  	CDN$	52,800	  	  	CDN$	194,400	  
		  	  
	  
	 	  	  
	  
	 

 Additional Consideration 

As consideration for an overhead cost of 15% of direct costs for a two (2) year period beginning on the Effective Date, the University shall receive an
option to purchase 30,000 shares of the Company’s Common Stock, representing 3% of the Company’s outstanding Common Stock upon formation, at an exercise price of US$1.00 per share (the “Options”). Commencing on the Effective
Date, the Options shall vest on a monthly basis over a two (2) year period, subject to continuation of research by the University under this Agreement, so that 1/24th of the Options shall vest each month during such two (2) year period.
The Options shall expire on August 31, 2009. 

  
 -11- 

 APPENDIX “C” 

Principal Investigator’s Undertaking 
  

	
	 Please return the signed original of this Undertaking to Melissa Jutzi at Research Services, Simcoe Hall, Rm. 133S, who can be reached at
978-6927 for information about the Research Agreement.
  

20/01/99

 PRINCIPAL INVESTIGATOR’S UNDERTAKING 

 

	RE:	Contract between the University of Toronto and Protagenic Therapeutics, Inc. for a project entitled “[[Project Title]]” (the “Project”) 

UNDERTAKING 
 I have read and received a copy of the above
referenced agreement (the “Research Agreement”) and agree with the terms and conditions contained therein. I will ensure that the Project is performed as outlined in the Research Agreement and will meet the obligations as specified in the
Research Agreement. I will authorize all project expenditures as outlined in the Research Agreement and the normal procedures and practices of the University, and in all matters will follow normal University policies and practices where they are not
replaced by specific conditions of the Research Agreement. 
 I will inform each person working on the Project, whether or not paid from Research
Agreement funds (the “Participant”), of the Participant’s obligations under the Research Agreement, and ensure that each Participant signs a Confidential Information and Intellectual Property Agreement in the form attached as
Appendix “D” to the Research Agreement (“IP Agreement”). I understand that any person who does not wish to sign an IP Agreement may not participate in the Project unless the University’s Office of Research Services
advises otherwise. 
 A list of Participants is provided on the reverse and a signed IP Agreement for each Participant is attached. I have indicated on the
reverse if any Participant’s work involves his or her thesis. If any person not listed on the reverse commences work on the Project, I will submit an additional IP Agreement for such person promptly upon his or her commencement of work, and I
shall update the list of Participants to include any such person. 
  

	
	 /s/ David Lovejoy

	Name: Professor David Lovejoy, Principal Investigator
	
	Date: December 9, 2004
	
	ACKNOWLEDGEMENT
	
	 /s/ James D. Thomson

	Name: Professor James D. Thomson, Chair, Department of Zoology
	
	Date: 9 December 2004

  
 -12- 

 Appendix “C-l” 

Project Participants 
  

					
	RE: Agreement with Sponsor:	  	Protagenic Therapeutics, Inc.	  	
	for Project:	  		  	
	by Principal Investigator:	  	Professor David Lovejoy	  	

 The following is a complete list of all persons who are working on the Project, whether or not paid from Research Agreement
funds, as of                     (Date). 

(student, postdoc, RA, technician, etc.) 
  

					
	 Name
	  	 Status
	  	 Involves Thesis

	 ARIJ AL CHAWAF
	  	PHD STUDENT	  	YES

 20/01/99 

  
 -13- 

 APPENDIX “D” 

Form of Confidential Information & Intellectual Property Agreement 

 

	
	 Each person working on the project, whether or not paid from Research Agreement funds, must sign and date this agreement. Please return a
signed original of this agreement to Melissa Jutzl at Research Services, Simcoe Hall, Rm. 133S, who can be reached at 978-6927 for information about the Research Agreement.
  

20/01/99

 Confidential Information & Intellectual Property Agreement 

The University of Toronto (the “University”) may make information and facilities for research available to me in connection with my work under a
contract between the University and Protagenic Therapeutics, Inc. (the “Sponsor”) for the project entitled “[[Project Title]]” (the “Research Agreement’’). Dr. David Lovejoy will supervise my work. 

In consideration of information and facilities made available to me and other valuable consideration, I agree that: 

 

	1.	I will keep confidential, in accordance with the terms of the Research Agreement, all of the Sponsor’s confidential information that I may receive. I will also keep the terms of the Research Agreement confidential.

  

	2.	I will comply with all publication conditions that may be set out in the Research Agreement. 

  

	3.	I will give complete information to the University’s Office of Research Services about any intellectual property, including without limitation, any technical information, know-how, copyright, model, drawing,
specification, prototype, invention, improvement, discovery, or software that I may make, conceive, develop, or reduce to practice in performance of the project (“Intellectual Property”) as may be requested by the University.

  

	4.	I will comply with all conditions regarding Intellectual Property that may be set out in the Research Agreement. 

  

	5.	All decisions about the protection of Intellectual Property under applicable legislation, ownership of and rights in any resulting application or patent, and revenue from Intellectual Property will be made in accordance
with the University of Toronto Inventions Policy dated effective January 1, 1990, as amended (http://www.research.utoronto.ca/policies_inventions.html). and/or the University of Toronto Copyright Policy dated June 3, 2002, as amended
(http://www.research.utoronto.ca/copyright.html), and the Research Agreement, and I will accept such decisions as final. 

  

	6.	I will sign all documents and do all things necessary or proper to give effect to this Agreement and any rights granted by the University under the Research Agreement. 

 

	7.	I have had an opportunity to review the applicable terms of the Research Agreement and obtain independent advice on the terms of the Research Agreement and my obligations and liabilities under this Agreement and the
Research Agreement. 

  

	8.	This Agreement shall be binding on my heirs. 

  
 -14- 

 By signing below, I indicate my acceptance of these terms. 

 

							
	 /s/ David Lovejoy
	  		  	 /s/ Gina Trubiani
	  	
	Signature	  		  	Witness	  	
				
	 David Lovejoy
	  		  	 Gina Trubiani
	  	
	Name (Type or Print)	  		  	Name (Type or Print)	  	
				
	 December 16, 2004
	  		  	 December 16, 2004
	  	
	Date	  		  	Date	  	

  
 -15- 

 Dr. D.A. Lovejoy: Research Plan 

for Protagenic Therapeutics, Inc. 
 Phase I Funding

 Time Scale: 6 months from onset of funding 

PROJECT TITLE: Evidence for existence of TCAP receptors in neurons. 

GOALS: 
  

	1)	Determination of the most appropriate cell line to evaluate TCAP ligand affinity for its receptor. 

  

	2)	Determination of cell lines that do not have TCAP receptors 

  

	3)	Determination of the most appropriate cell line in which to purify the TCAP receptor 

 Background: The
identification of eventual structural characterization of high affinity TCAP receptors are essential to develop a high sensitivity ligand-screening assay for the purpose of evaluating future TCAP peptide variants and ultimately as a high-throughput
testing platform to develop TCAP small molecule mimics. We have a unique advantage to develop a distinct receptor-screening assay by capitalizing on the use of the recently developed immortalized hypothalamic cell lines. We have screened these cells
for TCAP responsiveness and identified four cell lines that are responsive to TCAP as determined by cAMP modulation abilities. However, we have determined that cAMP is not a reliable endpoint as an evalution method. Many hormones can trigger an
increase in cAMP in some parts of the cell, for example neurites and axon hillock regions, but a decrease in dentrites. Thus using a monoculture of cells can lead to inconsistent results depending upon the confluency, passage and growth rate of the
cultured cells. Ligand-binding determinations are a more reliable determination as a first level of evalution of ligand activity because receptor activation is a prerequisite for downstream cellular activity such as cAMP. 

Experimental Design: Plasma membrane preparations of four different mouse neuronal cell line cultures will be used to measure the affinity of mouse
TCAP-l for the endogenous receptor. Cells will be grown initially to 50 to 60% confluency, as we have previously determined that this cell density is the most consistent in terms of TCAP action using neurite outgrowth and cAMP as physiological
endpoints. Receptor affinity will be evaluated using two methods: 1) Scintillation proximity assays (SPA) and 2) radioreceptor assays. The scintillation assay has the advantage in that it is already designed to be a high throughput method. It has
the disadvantage in that it has a lower sensitivity than other methods, and so the optimization of the cell type and receptor expression level are key requirements for an effective method. We have used this method in the past with ectopically
expressed receptors in a rapidly growing cell line. The radioreceptor assay, on the other hand is highly sensitive and specific using a radiolabelled TCAP ligand. We have used this method in the past to 

  

 
evaluate small sequence changes in peptides with a similar structure to TCAP. The disadvantage of this method is that it cannot be readily scaled up to a high-throughput level. Thus for the
purposes of defining the level of TCAP receptor expression and its affinity for its ligand, both methods are complementary. 
 Goal 1: Determination
of the most appropriate cell line to evaluate TCAP ligand affinity for its receptor. 
 TCAP affinity determined by as strong
response using the SPA assay, and confirmed by the radioreceptor assay will be selected as the cell line for high throughput screening 
 Goal
2: Determination of cell lines that do not have TCAP receptors. 
 A negative response in the form of a flat
displacement curve for both assays will be used as evidence that the TCAP receptor is not present. As further confirmation of this, a cAMP assay will be employed. 

Goal 3: Determination of the most appropriate cell line in which to purify the TCAP receptor 

Cell lines showing a strong affinity curve with a single binding site will be selected to for the purification of the receptor. Proteins with
affinity for TCAP will be examined using ligand photoaffinity cross linking to the bound protein. 
 Challenges and Interpretation: Although we
already possess cell lines with the TCAP receptor that can yield a measurable response, high levels of receptor expression are essential for a sensitive screening assay. Endogenously expressed receptors may not be expressed at a level that is viable
for a screening assay that can be scaled up to a high-throughput type level. In this case, it may be necessary to explore additional heterologous systems where the TCAP receptor is ectopically expressed in for example non-neural cells using a vector
system incorporating a high expression promotor (e.g. CMV). We have utilized a similar system in the past to evaluate novel peptide designs and, therefore, have the experience to develop this further, if necessary. Our preliminary investigations
also indicate that the affinity of the TCAP receptor may be altered by the presence of GPCR-modulating proteins, particularly the RAMP proteins. Thus, if using a heterologous expression system, the appropriate RAMP may have to be coexpressed.
Alternatively, if receptor levels are of sufficiently high levels in the homologous neuronal systems, then using the appropriate cell line with the requisite accessory proteins will be essential. 

Timelines 
 The setting up and optimization of the
receptor assay systems are expected to take about 2 months. Determination of the appropriate cell lines are expected to take 2-4 months depending of the data obtained. Within this period we will know whether an endogenously 

  

 
expressed receptor system or an ectopically expressed receptor system is more sensitive to evaluate the compounds. About 2 to 4 months will be required to evaluate the levels of TCAP bound
protein in the responsive cell lines. A number of the project goals can be done in parallel to each other such that about 6 months will be required to answer these questions. 

Personnel: An entry-level post-doctoral scientist with a background in molecular pharmacology will be responsible for the setting up and optimization
of the assay, as well as the analysis of the peptide binding curves. This individual will also be responsible for organizing the testing regimens and in consultation with Dr. Lovejoy making the decision on the appropriate cell lines and
preparing the data reports. A junior research assistant is will be required for the preparation and maintenance of the cell lines as well as assist as necessary in the preparation of the cell and membrane extracts. The scientist in training, Arij Al
Chawaf, presently a Ph.D student in Dr. Lovejoy’s laboratory, who has been developing the receptor characterization assays will evaluate the cell lines selected for the purification of the receptor using photo affinity cross-linking
purification. 
 Phase / Budget: Evalution of TCAP receptor affinity in immortalized neurons 

 

							
	 Personnel
	  	Post Doctoral Scientist	  	 	21,000	  
		  	Research Assistant	  	 	12,500	  
		  	Scientist in training	  	 	2,000	  
		  	total	  	 	35,500	  
	 Consumables
	  	SPA kits	  	 	7,000	  
		  	Radioisotopes	  	 	2,500	  
		  	disposable labware	  	 	800	  
		  	chemicals	  	 	500	  
		  	Electrophoresis	  	 	5500	  
		  	Tissue culture	  	 	1000	  
		  	total	  	 	17,300	  
		  	grand total	  	 	52,800	  

  

 AMENDING AGREEMENT #1 between 

Protagenic Therapeutics, Inc. and the Governing Council of the University of Toronto 

 
 This AMENDING AGREEMENT (the “Amending
Agreement”) made in duplicate the 31st day of May, 2005. 
 BETWEEN: 

PROTAGENIC THERAPEUTICS, INC. 

(the “Company”) 
 -and-

 THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO 

(the “University”) 
 WHEREAS the Company
and the University entered into an agreement effective December 14, 2004 (the “Research Agreement”) for the performance of a research project entitled “Evidence for existence of TCAP receptors in neurons” (the
“Project”); 
 AND WHEREAS the parties now wish to amend the Research Agreement herein; 

The parties hereby agree as follows: 
 1. Definitions.
Except as otherwise defined herein, any capitalized terms used in this Amending Agreement shall have the meanings prescribed by the Research Agreement The capitalized terms “First Installment,” “Second Installment,” and
“Final Installment” shall have the meaning prescribed in Appendix “B” attached hereto. 
 2. Budget. The University has received
$52,800 of the $247,200 due to the University for carrying out the Project. The Company shall provide the remaining budget of $l94,400 in accordance with the revised budget and payment schedule attached as Appendix “B”, which shall replace
Appendix “B” of the Research Agreement. 
 3. Payment. The First Installment from the Company was paid by cheque on December 1, 2005. The
Second Installment will be paid in equal installments over the six (6) month period of June 1, 2005—November 31, 2005 on the first of every month. The Final Installment will be paid on the date which is six (6) months after
the final execution of the License Agreement. 
 4. Research Plan. In accordance with Section 1 of the Research Agreement, the research plan set
forth in Appendix “A” to the Research Agreement is supplemented by the research plan attached as Appendix “A” to this Amending Agreement. 

5. Financial Reports. For six month period of the Second Installment, the University will provide the Company with financial reports from time to time
summarizing the expenses incurred within a reasonable time after the Company’s request therefor. 
 6. General. All other terms of the Research
Agreement and the Administration Agreement shall remain unchanged and in full force and effect. 
 In witness whereof the parties agree to be bound by the
terms of this Amending Agreement 
  

									
	THE GOVERNING COUNCIL OF THE	 		 	PROTAGENIC THERAPEUTICS, INC.
	UNIVERSITY OF TORONTO	 		 	
			
	 /s/ Peter B. Munsche
	 		 	 /s/ H. Hartounian

	Name:	 	Peter B. Munsche	 		 	Name:	 	H. Hartounian
	Title:	 	Assistant Vice-President	 		 	Title:	 	Chairman
		 	Technology Transfer	 		 		 	

  

 Acknowledgement: 

I, the Principal Investigator having read this Agreement, hereby agree to act in accordance with all the terms and conditions herein and to agree to ensure
that all University participants are informed of their obligations under such terms and conditions. 
  

	
	 /s/ David Lovejoy

	Prof. David Lovejoy, University of Toronto, Department of Zoology

  

 Appendix “A” 

PTI Research Plan 

Viability of TCAP as an Intravenously Injected Therapeutic 

David Lovejoy and Susan Rotzinger 

Strategy and Goals 
 The aim is to establish a complete
physiological model of TCAP action from exogenous administration to the onset of behaviour with the goal to establish the feasibility of TCAP treatment on hospitalized patients suffering from severe depression or anxiety. Several experiments are
proposed to fill in the gaps where the understanding of TCAP action is not complete. 
 At the completion of these studies, we should be able to determine
the best method to administer TCAP, its longevity in vivo (biological half-life), its uptake in the brain, its mode of action on key sites in the brain and how it targets the CRF-mediated anxiogenic system, its actions on behavioural tests.
Moreover, its actions on behavioural tests should allow predictions as to whether TCAP will be most appropriate for treating depression or anxiety. 

Proposed Experiments 
 Development of New Assay
Systems 
 In order to enhance our understanding of the actions of TCAP two new assay systems will be developed. 

Forced Swim Test: Presently, our behavioural analyses are designed to evaluate the anxiolytic or anxiogenic aspects of bioreactive agents. However, the
forced swim test is the industry standard test for evaluating whether an agent has the potential to modify the incidence of depression. This method is presently not being used in-house and therefore we need to purchase the necessary equipment and
validate the test on TCAP treated animals in comparison to animals treated with agents known to enhance depression. 
 TCAP Radioimmunoassay: In
addition, the accurate detection of TCAP in the blood stream may be a powerful tool to determine if individuals are predisposed to the incidence of depression and anxiety or are suffering from a condition associated with TCAP dysregulation.
Moreover, a TCAP detection assay will allow for an understanding of the biological halflife of TCAP and in the future could be used to monitor patients undergoing TCAP treatment. If TCAP can be reliably detected in plasma then we envision using the
ratio of plasma TCAP concentrations to known anxiogenic hormones such as CRF, ACTH and cortisol as a diagonostic means to detect the incidence of depression and anxiety. We have already raised three TCAP-specific antisera, and possess the necessary
equipment to put this assay together. 

  
 page 1 

 Route of Administration 

Presently most studies have focused on direct injection of TCAP into the brain using indwelling cannulae. Pilot studies indicate that intravenous injection is
a viable method, although a full set of behavioural experiments to ascertain this have not been performed. In addition, subcutaneous injection has not been investigated. 

TCAP will be administered either as a single injection IV or SC to determine acute effects, or as one injection each day over five days to determine chronic
actions. The acoustic startle response, elevated plus maze, swim test behaviour locomotion and body weight changes will be examined 
 Biological
Half-life 
 Nothing is presently known about the longevity of TCAP in vivo. A structural analysis of the peptide predicts that TCAP is modified for
circulation in the blood stream. Two sets of experiments are designed to answer these questions. 
 Synthetic TCAP will be incubated in rat plasma, and its
breakdown by proteolytic enzymes will be determined by examining the loss of immunoreactive signal on a high resolution polyacrylamide gel using TCAP-specific antisera over a 2 to 8 hour period. The length of time will be based on its rate of
breakdown in the first 1 to 2 hours of the study. This will allow us to understand the plasma component of TCAP degradation. 
 Upon completion of the above
experiments, TCAP will be injected intravenously into rats and the presence of TCAP in tissues and the brain will be examined by radioimmunoassay. TCAP expression 

Tissue partitioning Studies 
 Pilot studies on IV
injected TCAP reveal that this mode of administration induces behavioural changes consistent with the actions of neurally injected TCAP. This implies that TCAP is moving across the blood brain barrier to gain access into the brain, but does not rule
out an indirect action of TCAP on other organ systems that possess a feedback action on the brain, for example the adrenal cortex. 
 TCAP uptake in the
brain will be examined directly by the expression of labelled TCAP in the brain after IV injection of labelled TCAP. Any major modification of the TCAP sequence either by adding a novel epitope or by chemoluminescent tagging will likely modify TCAP
uptake by putative transporter and receptor systems. Thus a radiolabel tag will likely be employed. 

  
 page 2 

 Interactions with CRF and its receptor system 

The acoustic startle response studies indicate that TCAP may act directly on its own receptor to induce an anxiolytic response or alternatively may act as an
antagonist on the CRF-receptor system to inhibit the actions of CRF. These studies are designed whether TCAP can directly inhibit the actions of CRF acutely or chronically through the CRF-R1 receptor system. 

TCAP and CRF will be coinjected IV at varying concentrations to determine actions on ACTH release from the pituitary and cortisol release from the adrenal
cortex. Previous studies by our laboratories indicate that TCAP by itself does not induce cortisol release. However a non-significant but compelling decrease in plasma cortisol was observed in animals treated with TCAP. These studies will be
repeated in vitro using a cell line that possesses the CRF-R1 receptor. 
 Project Costs 

 

											
	 Project
	  	 Experiment
	  	 Item
	  	 Description
	  	Total Cost	 
	 Administration Route
	  	Subcutaneous injection	  	Animals	  	80 sprague dawley rats	  	$	2,235.20	  
		  	Intravenous injection	  	Animals	  	80 sprague dawley rats	  	$	2,235.20	  
	 New behavior models
	  	Forced swim test	  	 Animals
 equipment
	  	 100 sprague dawley rats

chambers
	  	$
 $
	2,794.00
 1,000.00
	  
   

	 In Vivo CRF-R1 studies
	  	TCAP/CRF interaction	  	Animals	  	80 sprague dawley rats	  	$	2,235.20	  
	 Behavioural Studies
	  	General	  	Personnel	  	Full time animal technician	  	$	20,000.00	  
		  		  	Consummables	  	 Surgical supplies
 Pharmaceuticals

Misc lab supplies
	  	$
 $
 $
	4,000.00
 1,000.00

1,000.00
	  
   

  

	 Development of TCAP assay
	  		  	 Animals
 Consummables

Consummables
 Consummables

Consummables
	  	 20 sprague dawley rats
 isotopes

secondary antisera
 scintillation tubes and reagents

misc lab supplies
	  	$
 $
 $

$
 $
	558.80
 3,000.00

2,000.00
 2,000.00

1,500.00
	  
   

  
   

  

	 TCAP degradation studies
	  	In vivo	  	 animals
 connsumables
	  	 10 sprague dawley rats
 electrophoresis
reagents
	  	$
 $
	279.40
 2,500.00
	  
   

		  	In vitro	  	 animals
 connsumables
	  	 10 sprague dawley rats
 electrophoresis
reagents
	  	$
 $
	279.40
 1,000.00
	  
   

	 TCAP partitioning studies
	  	Synthetic TCAP injection	  	 Animals
 consummables

consummables
	  	 40 sprague dawley rats
 Radioimmunoassay
reagents
 Misc lab supplies
	  	$
 $
 $
	1,117.60
 1,000.00

1,000.00
	  
   

  

	 Peptide Studies
	  	General	  	personnel	  	Full time post doctoral scientest	  	$	17,500.00	  
	 Total
	  		  		  		  	$	70,234.80	  

  
 page 3 

 Project Timeline 
  

 

  
 page 4 

 AMENDING AGREEMENT #1 between 

Protagenic Therapeutics, Inc. and the Governing Council of the University of Toronto 

 
 APPENDIX “B” 

Revised Budget 
 Cash Payment

  

							
	 	  	First Installment	  	Second Installment	  	Final Installment
	 Direct Costs
	  	CDN$45,913	  	CDN$70,235	  	CDN$98,808
	 O/H Cash
	  	CDN$6,887	  	CDN$10,535	  	CDN$14,822
	 Total Cash
	  	CDN$52,800	  	CDN$80,770	  	CDN$113,630

 Additional Consideration 

As consideration for an overhead cost of 15% of direct costs for a two (2) year period beginning on the Effective Date, the University shall receive an
option to purchase 30,000 shares of the Company’s Common Stock, representing 3% of the Company’s outstanding Common Stock upon formation, at an exercise price of US$1.00 per share (the “Options”). Commencing on the Effective
Date, the Options shall vest on a monthly basis over a two (2) year period, subject to continuation of research by the University under this Agreement, so that 1/24th of the Options shall
vest each month during such two (2) year period. The Options shall expire on August 31, 2009. 

  

 Schedule C 

Milestones 
  

					
	 Event
	  	Payment	 
	 IND submitted after efficacy demonstrated in non-human primates (“IND Submission”), per IND candidate
	  	$	100,000	  
	 Phase I End
	  	$	100,000	  
	 Phase II End
	  	$	100,000	  
	 Phase III End
	  	$	100,000	  

  
 Page 23 of 24 

 Schedule D 

University of Toronto Confidential Invention Disclosure 

  
 Page 24 of 24 

 Appendix A 
  

			
	

	  	 UNIVERSITY OF TORONTO INVENTIONS POLICY

CONFIDENTIAL INTELLECTUAL PROPERTY DISCLOSURE
 Office of the Vice
President • Research and Associate Provost
 27 Kings College Circle, Room 133-S

Tel: (416) 978-7833 Fax: (416) 978-5821 email: monique.mcnaughton@utoronto.ca

 
  

1. Title: Selected Targeting of Residue Motifs (STORM): a novel algorithmic method to predict bioactive peptides in genome databases 

2. a) University of Toronto Inventors/Major Contributors: 
  

									
	SURNAME, GIVEN NAMES	  	UNIVERSITY
PERSONNEL
NO.	  	DEPARTMENT (LIST
ANY CROSS
APPOINTMENTS OR
AFFILIATED
INSTITUTIONS)	  	AFFILIATION WITH
UNIVERSITY (i.e.,
faculty, res. assoc., post-
doc, student, staff, visitor,
etc.)	  	CURRENT ADDRESS, PHONE,
FAX, EMAIL
	 Lovejoy, David A.
	  	001012872	  	Zoology	  	Faculty	  	 25 Harbord St
 t. (416) 946-7259

f. (416) 978-8532
 dlovejoy@zoo.utoronto.ca

 2. b) External Inventors/Major Contributors: 

(Please provide names and affiliations of non-University of Toronto individuals who have made a creative contribution to this Intellectual
Property, i.e. sponsor employees, academic collaborators, etc.) 
 No external inventors or contributors were part of the development of this intellectual
property 
 3. Description: 
 (Please
highlight the novelty or patentable aspects of this Intellectual Property; attach a separate sheet if necessary) 
 STORM is an algorithm to identify the
functional regions in a peptide by examining the structure of orthologous peptides across taxa, and the structure of paralogous peptides within taxa. STORM is unique from other algorithmic methods to predict structure by its use of comparative
phylogenetic information to determine the probability of particular amino acid substitutions within a sequence. Thus STORM utilizes animal phylogeny models based on both palaeontological data as well as molecular data. This information is used to
construct a hypothetical functional ancestor where sets of common amino acid motifs are identified. The sequence and relative position of the motifs are used to search databases for related sequences. STORM can therefore be used to discover new
bioactive proteins and peptides, new functions of known peptides and proteins, functional regions within peptides and proteins, and to design new peptides with novel properties. 

 

	
	DATE RECEIVED:   November 19, 2004  
                              DISCLOSURE REFERENCE NO.:   10001238  

   Confidential Intellectual Property Disclosure (inventions Policy) 

January/03 

  
 Page 1 of 2 

 4. How was the work leading to this Intellectual Property funded? i.e., salaries, equipment used, supplies,
etc. 
 This work has not been funded. 
  

					
	 SPONSOR
	 	 GRANT OR CONTRACT FUND #
	 	 INTELLECTUAL PROPERTY

TERMS & CONDITIONS

	 n/a
	 	n/a	 	n/a

 5. Where did the work leading to this Intellectual Property take place? 

The STORM algorithm was developed entirely at the Dept of Zoology, University of Toronto, as a means of attempting to identify new families of peptides
associated with stress and anxiety. 
 6. Is this Intellectual Property subject to any software licence, material transfer, confidentiality,
nondisclosure, collaboration or other agreement, written or oral, not referenced In Section 4? 

x NO
             ̈ YES (If “Yes”, please provide details) 

7. What are the potential applications and/or sources of revenue from this Intellectual Property? 

The STORM algorithm can be used to identify new peptide hormones, their receptors and regulatory proteins. These in tum can be used as targets for the
development of new pharmacological therapeutics. STORM can also be used to design amino acid (ie peptide) based drugs. With respect to basic science STORM can be used to identify previously unknown paralogous peptide and proteins to understand the
physiological regulation of a particular system and also help establish the phylogenetic interrelationships of species. Thus the STORM algorithm is likely to be of interest to scientists in both commercial and academic settings. 

8. Warranty: 
 I/We, the Inventors/Contributors listed in
Section 2(a), have read, understood and agree to all of the preceding and declare that all of the information provided in this disclosure is complete and correct. To the best of our knowledge, all persons who might legally make an ownership
claim in this Intellectual Property are identified in Section 2(a) and 2(b). 
  

			
	 /s/ David Lovejoy
	 	 Nov 14

	Signature	 	Date
	Typed Name:	 	
	 David Lovejoy
	 	

 For more information on University of Toronto Intellectual property policies, please call 416-978-7833 or access
http://www.library.utoronto.ca/techtran/. 
 For information on commercialization processes and procedures please call the Innovations Foundation at
416-978-5117. 
 Confidential Intellectual Property Disclosure (Inventions Policy) 

January/03 

  
 Page 2 of 2EX-10.19(ii)

 Exhibit 10.19(ii) 

FIRST AMENDMENT TO TECHNOLOGY LICENSE AGREEMENT 

THIS FIRST AMENDMENT TO TECHNOLOGY LICENSE AGREEMENT (the “License Amendment”) is made and entered into as of February 18, 2015
by and between THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (“UT’’), a corporation vested with the government, management and control of the University of Toronto by the University of Toronto Act, 1971 and having offices
at Banting Institute, 100 College Street, Suite 413, Toronto, Ontario, Canada, M5G 1L5 and PROTAGENIC TIIERAPEUTICS, INC. a corporation incorporated under the laws of Delaware and having a principal place of business at 149 5th Avenue, Suite
500, New York, NY 10010, U.S.A. (“Licensee”). 
 BACKGROUND: 

 

	 	A.	The Licensee and the University of Toronto Innovations Foundation (“UTIF”) entered into a technology license agreement effective July 21, 2005 (“License Agreement”).

  

	 	B.	Effective May 1, 2006, UTIF ceased to operate its business and it transferred and assigned all of its business and assets to UT and the License Agreement continued under the same terms and conditions aside from UT
replacing UTIF in said License Agreement. 

  

	 	C.	UT and Licensee entered into a sponsored research agreement dated December 14, 2004, as amended May 31, 2005; December 11, 2006; April 16, 2007; March 17, 2008; March 18,
2009; February 1, 2011; February 21, 2011; May 18, 2011; April 1, 2012; and April 1, 2013 and may enter into additional sponsored research agreements (collectively the “Research Agreement”).

  

	 	D.	UT and Licensee wish for improvements (as defined in the License Agreement and listed under Schedule A hereto), created by David Lovejoy and/or other research participants under the Research Agreement while employed by
UT, to be included in the License. 

  

	 	E.	UT and Licensee wish to amend the License Agreement in accordance with the conditions hereof. 

 NOW
THEREFORE, the Parties hereto agree to further amend and revise the License Agreement as follows:  
 All capitalized terms not defined herein
shall have the same meaning ascribed to such terms as set out in the License Agreement. 

	1.	All references to the University of Toronto Innovations Foundation and “UTIF” are hereby deleted and replaced with The Governing Council of the University of Toronto and “UT” respectively.

 2. Section 1.1 -Definitions. 

The definition of “Improvements” is hereby deleted in its entirety and replaced with the following:  

“Improvements” means any and all improvements, variations, updates, modifications or enhancements to the Technology (including
without limitation any related Intellectual Property Rights) which are developed under the terms of a research agreement dated December 14, 2004, as amended May 31, 2005; December 11, 2006; April 16,
2007; March 17, 2008; March 18, 2009; February 1, 2011; February 21, 2011; May 18, 2011; April 1, 2012; and April 1,2013, and under the terms of any other sponsored research agreement
designated in same as being added by reference to Schedule B of this Agreement and this Agreement shall be deemed to be amended accordingly to incorporate all such sponsored research agreements as a Research Agreement by reference between Licensee
and The Governing Council of the University of Toronto. 
 The definitions of “Phase I End”, “Phase II End” and
“Phase III End” are hereby deleted in their entirety and replaced with the following:  
 “Phase I
End” means approval by the FDA or other applicable regulatory authority to commence Phase II Clinical Trials of each Licensed Product as such trials are described in 21 C.F.R. 312.2 l(b); 

“Phase II End” means approval by the FDA or other applicable regulatory authority to Commence Phase III Clinical Trials of
each Licensed Product as such trials are described in 21 C.F.R.3 12.21(c); 
 “Phase III End” means Regulatory
Approval of each Licensed Product; 
 The definition for “University” is hereby deleted in its entirety and replaced with the
following:  
 “University” means The Governing Council of the University of Toronto. 

3. Section 2.1(a) -Grant of License for Technology 

Section 2.1 (a) is hereby deleted in its entirety and replaced with the following; 

(a) an exclusive license within the Territory and within the Field of Use to develop, make, have made, use, sell, offer for sale and import the Technology and
Licensed Products under all Owners’ and/or David Lovejoy’s and or UT rights, title and interest in the Technology and Licensed Products; and 

 4. Section 3.1 -Royalty 

Section 3.1(f) is added as follow: 
 f) For clarity, Upfront
Sub-License Fees shall exclude any and all research and development payments, reimbursements, loans and equity investments in the Company and payments made in respect of a collaboration agreement or acquisition agreement, whether such payments are
for research milestones or otherwise, supply of product and similar arrangements. 
 5. Section 4.1 -Ownership 

Section 4.1 is hereby deleted in its entirety and replaced with the following: 

All Intellectual Property Rights in all aspects and parts of the Technology and Improvements shall be exclusively owned by the Owners, and/or David Lovejoy
and/or the UT as the case may be and nothing herein shall serve to, or should be construed to transfer any Intellectual Property Rights whatsoever in the Technology or Improvements except to the extent that any such Intellectual Property Rights are
developed solely by the Licensee (with or without a third party) in which case the Licensee shall own or co-developed with the Licensee, in which case the Licensee shall have co-ownership rights in same as applicable. 

6. Section 4.3 -Patents and Patent Applications. 

Section 4.3 (a) is hereby deleted in its entirety and replaced with the following: 

 

	 	(a)	Licensee, in the name of the Owners, and/or David Lovejoy and/or UT (and as the case may be the Licensee if a joint developer) as the case may be, as assignee, shall file, prosecute and maintain the Patents. Licensee
shall determine in which countries to pursue patent applications. In the event that Licensee elects not to continue prosecution in any country, UT may, at its sole discretion, file such patent or continue such prosecution in that country at its own
expense. In such cases, any patents arising from such applications shall be excluded from the grant of rights under Section 2.1 herein for said country. 

Section 4.3 (e) is hereby deleted in its entirety and replaced with the following: 

 

	 	(e)	Licensee undertakes to keep UT reasonably advised of the progress of prosecution and of any actions Licensee proposes to take or has taken in connection with the prosecution or maintenance of the Patents. Licensee shall
provide UT with copies of correspondence and all actions issued by patent authorities and shall take into account any comments, remarks or suggestions UT may promptly provide to Licensee in writing at least ten (10) days prior to any due date
established by Licensee for preparation of a response or amendment, and in all cases thirty (30) days prior to any patent office due date. 

 7. Section 4.4 -Improvements 

Section 4.4 is hereby amended by replacing the phrase at the third line, “the name of the Owners, or David Lovejoy” with the name of the Owners
and/or David Lovejoy and/or UT (and, as the case may be) the Licensee if a joint developer)” 
 8. Section 7 -Notices. 

Section 7.3 (a) is hereby deleted and replaced with the following: 
  

	(a)	In the case of a notice to Licensee: 

 Protagenic Therapeutics, Inc. 

149 5th Avenue, 
 Suite 500, New
York, NY 10010 
 U.S.A. 

Attention: Robert Ziroyan, PhD, MSc 

E-mail: robert.ziroyan@me.com  

With a copy to: 
 Gowlings
Lafleur Henderson LLP 
 1 First Canadian Place 

100 King Street West Suite 1600 

Toronto, Ontario M5X 1G5 
 Canada

 Attention: Anita Nador 

E-mail: anita.nador@gowlings.com 

Section 7.3 (b) is hereby deleted and replaced with the following: 
  

	(b)	In the case of a notice to UT: 

 Innovations and Partnerships Office 

Banting Institute, 100 College Street, Suite 413 

Toronto, Ontario M5G lL5 
 Canada

 Attention: Jennifer Fraser 

Director, Innovations 
 E-mail:
jen.fraser@utoronto.ca 
  

	9.	Schedule “A” is hereby amended by including the additional Improvements (Confidential Intellectual Property Disclosures & related Patents and Patent Applications) under the Schedule. 

	10.	Schedule “B” is hereby amended by incorporating by reference the 2012 and the 2013 Sponsored Research Agreements to the Schedule and any other Research Agreement designated in same as being added by reference
to Schedule B of the License Agreement between Licensee and The Governing Council of the University of Toronto. 

  

	11.	Except as set out herein, this License Amendment shall not amend or modify any other provision within the License Agreement. 

  

	12.	This License Amendment shall be governed by the laws of the Province of Ontario and the federal laws of Canada applicable in the Province of Ontario 

IN WITNESS OF WHICH the Parties hereto have executed this First Amendment. 
  

							
	PROTAGENIC THERAPEUTICS, INC.	  	THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
				
	By:	  	 /s/ Robert Ziroyan
	  	By:	  	 /s/ Jennifer Fraser

	Name:	  	Robert Ziroyan, PhD, MSc	  	Name	  	Jennifer Fraser
	Title:	  	Chief Operating Officer, President	  	Title:	  	Director, Innovations

 SCHEDULE A 

Additional Improvements 
 Project Ref:
P1323 
 Copies of listed Invention Disclosures Attached 
  

											
	 S.No.
	  	 Confidential
Invention
Disclosure
Number
	  	 Date of
Disclosure
	  	 Named
Internal
Inventors
	  	 Title of Disclosure
	  	 Date of
Assignment to
Inventors

	1.	  	10002701	  	Jan 16, 2014	  	David Alan Lovejoy	  	Treatment of Insulin-Resistant Hyperglycemia by Teneurin C-Terminal Associated Peptide-1	  	Feb 18, 2015
	2.	  	10002574	  	Mar 27, 2013	  	David Alan Lovejoy; Chand Dhan	  	Treatment of Human male Infertility by Use of Teneurin C-Terminal Associated Peptide (TCAP- 1) Administration	  	March 3, 2015

			
	

	 	UNIVERSITY OF TORONTO
	 	CONFIDENTIAL INTELLECTUAL PROPERTY DISCLOSURE
	 	Banting Institute, Room 413
	 	100 College Street, Toronto, ON M5G 1L5
	 	Tel: (416) 978-7833 Fax: (416) 978-5821 email: ip.officer@utoronto.ca

 1. Title of Invention: Treatment of insulin-resistant hyperglycemia by teneurin C-terminal associated peptide-1
administration 
 2. a) University of Toronto Inventors Individuals intimal to the University who have made an inventive contribution to
this Invention i.e. faculty, students, postdocs, staff etc. Attach extra sheet if necessary: 
  

											
	 SURNAME,

GIVEN NAMES
	 	 UNIVERSITY

PERSONNEL
 NO.
	 	 DEPARTMENT

(List any cross
appointments or affiliated
institutions)
	 	 AFFILIATION
	 	 EMAIL ADDRESS
	 	 CONTACT

INFORMATION
 (mailing address

phone, fax)

	 Lovejoy
 David Alan
	 	001012972	 	 Cell and
 Systems

Biology
	 	Professor	 	 David.lovejoy@
 Utoronto.ca
	 	 Tel: cell: 647 999
 2977, home: 905

642 4616
  

Address: 149
 Baker Street,

Stouffville,
 Ontario, L4A

1K6

 b) External Inventors Non-University of Toronto Individuals who have made an inventive contribution to the Invention.
i.e. sponsor employees, academic collaborators, etc. List name, organization and e-mail address. 
 not applicable 

 

			
	 For Research Services use only: 
 Date Received:
JAN 16 2014
	 	 DISCLOSURE REFERENCE NO: 10002701

 Version: 2011.09.08 

	 	c)	Contributors Individuals Internal or external to the University who have not made an Inventive Contribution to this Invention but have made a valuable contribution to the development of the Invention. List
name organization and e-mail address. 

 Protagenic Therapeutics Inc provided the majority of the funding for this project 

Contact: Dr. Robert Ziroyan: rziroyan@protagenic.com 

3. Where did the work leading to this Invention take place? Please be specific 

In vitro studies were conducted in rooms 304, 305 in Ramsay Wright Building at the University of Toronto. Animal studies were conducted in the
Biosciences Support Facility central vivarium at Ramsay Wright. Hormone studies were performed under contract by Rules Based Medicine, a contract research organization (CRO) 

4. Invention Description Please provide a description of this Invention for evaluation, highlighting its novel or patentable aspects. Attach a separate
sheet if necessary. 
 TCAP-l is a 41 amino acid peptide derived from a natural protein (teneurin) found in the human reproductive organs and
other tissues. It acts to regulate cell metabolism via a unique mechanism associated with activation of the dystroglycan complex leading to a signal transduction cascade to increase the number of glucose transporters in the cell membrane thereby
increasing the transport of glucose into the cell. This action leads to significantly higher cellular energy in the form of increased cellular ATP levels. At the organismal level, single doses of TCAP-1 at 300 and 3000 pmoles significantly decrease
blood glucose levels as long as one week later. 
 5. Have there been any prior disclosures (abstracts, presentations, publications) in respect of this
Invention? List them and provide the date each disclosure occurred. 
 Chen C. Song L. de Lannoy L, Xu M, Crosier R, Lovejoy DA
(November. 2013) Insulin independent glucose transport and enhanced neuron metabolism by Teneurin C-terminal Associated Peptide (TCAP)-l Society for Neuroscience. San Diego, USA 

 

	6.	a) How was the work leading to this Invention funded? (I.e. salaries, equipment used, supplies 

 etc.) 

 

					
	 SPONSOR
	  	 PROJECT TITLE
	  	 RIS FUND #

	Protagenic Therapeutics Inc	  	Evidence for the existence of TCAP receptors	  	495550

 b) Was the project/work leading to this Invention subject to any software licence, material
transfer, confidentiality, non-disclosure, collaboration or other agreement, written or oral, not referenced in (a) above? 
 x NO         ̈ YES (please provide details) 
  

	7.	Have any patent applications or other intellectual property protection been filled in respect of this invention? 

 ̈ NO        
x YES (please provide details) 
  

	 	1.	AUSTRALIA: September 2010. Patent Number: (May 2, 2003) 2003221575 Teneurin c-terminal associated peptides (tcap) and methods and uses thereof Inventors: LOVEJOY, David; CHEWPOY, R. Bradley; BARSYTE, Dalia;
ROTZINGER, Susan. 

  

	 	2.	UNITED STATES. August 26, 2011. Patent Number 10/510959. Teneurin c- terminal peptides (TCAP) and uses thereof LOVEJOY, David; CHEWPOY, R. Bradley; BARSYTE, Dalia; ROTZINGER, Susan.

 8. Warranty: 
 I/We the Inventors
listed in Section 2(a), have read, understood and agree to all of the preceding, and declare that all of the Information provided in this disclosure is complete and correct. To the best of our knowledge, all persons who might legally make an
ownership claim in this Invention are identified in Section 2(a) and 2(b). 
  

									
	/s/ David A. Lovejoy	  		  	 	  	 
	Signature	  	Date: 01/14/2014	  		  	Signature	  	
	 Typed Name:
  
	  	David A. Lovejoy	  		  	Typed Name:	  	 
	Signature	  	Date	  		  	Signature	  	Date
	Typed Name:	  		  		  	Typed Name:	  	

			
	

	  	UNIVERSITY OF TORONTO
	  	CONFIDENTIAL INTELLECTUAL PROPERTY DISCLOSURE
	  	Banting Institute, Room 413
	  	100 College Street, Toronto, ON M5G 1 L5
	  	Tel: (416) 978-7833 Fax: (416) 978-5821 email: ip.officer@utoronto.ca

 1. Title of Invention: Treatment of human male infertility by use of teneurin C-terminal associated peptide (TCAP)-1
administration 
 2. a) University of Toronto Inventors Individuals internal to the University who have made an inventive contribution to
this Invention i.e. faculty, students, postdocs, staff etc. Attach extra sheet if necessary: 
  

											
	 SURNAME,

GIVEN
NAMES
	  	 UNIVERSITY

PERSONNEL
 NO.
	  	 DEPARTMENT

(List any cross
appointments or
affiliated
institutions)
	  	 AFFILIATION
	  	 EMAIL ADDRESS
	  	 CONTACT

INFORMATION
 (mailing address

phone, fax)

	 Lovejoy
 David Alan
	  	001012972	  	Cell and Systems Biology	  	Professor	  	David.lovejoy@utoronto.ca	  	 Tel: 647 999 2977
 Dept of Cell
of
 Systems Biology
 Ramsay Wright

Bldg. 25 Harbord
 Street, University of Toronto

						
	 Chand
 Dhan
	  	993001103	  	 Cell and
 Systems

Biology
	  	Ph.D. Graduate	  	 Dhan.chand
 @mail.utoronto.ca
	  	 Tel: 416 209 0826
 Dept. of Cell of Systems
Biology
 Ramsay Wright
 Bldg. 25 Harbord street. University of
Toronto

 b) External Inventors Non-University of Toronto individuals who have made an inventive contribution to the Invention,
i.e. sponsor employees, academic collaborators, etc. List name, organization and email address. 
 not applicable 

c) Contributors Individuals internal or external to the University who have not made an inventive contribution to this Invention but have made a
valuable contribution to the development of the Invention. List name, organization and e-mail address. 
 Protagenic Therapeutics Inc provided the majority
of the funding for this project 
 Contact: Dr. Robert Ziroyan: rziroyan@protagenic.com 

 

			
	 For Research Services use only:
 Date Received:
Mar 27 2013
	 	 DISCLOSURE REFERENCE NO: 10002574

	3.	Where did the work leading to this Invention take place? Please be specific. 

 In vitro
studies were conducted in rooms 304, 305 in Ramsay Wright Building at the University of Toronto. Animal studies were conducted in the Biosciences Support Facility central vivarium at Ramsay Wright. Hormone studies were performed under contract by
Rules Based Medicine a contract research organization (CRO). 
  

	4.	Invention Description Please provide a description of this Invention for evaluation, highlighting its novel or patentable aspects. Attach a separate sheet if necessary. 

TCAP-l is a 41 amino acid peptide derived from a natural protein (teneurin) found in the human reproductive organs and other tissues. It acts
to regulate cell metabolism via a unique mechanism associated with activation of the dystroglycan complex. In the male reproductive system the teneurin-dystroglycan complex is associated with regions of the testes and epididymis that play a role in
spermatozoa formation, maturation and viability. In vivo studies indicate that synthetic TCAP-l modifies testicular and epididymal morphology increases testes size and increases testosterone production. These effects are consistent with increased
activity of the reproductive system in mate mice. However because the peptide and hormone system is highly conserved in all mammals as well as vertebrates in general, these studies suggest that synthetic TCAP-l has potential to be used to treat some
forms of male infertility in humans as well as other species. 
  

	5.	Have there been any prior disclosures (abstracts, presentations, publications) in respect of this invention? List them and provide the date each disclosure occurred. 

Chand D, Colacci M, Dixon K, Lovejoy DA. (2012). Gonadal characterization of the evolutionary conserved teneurin-dystroglycan system in mouse.
26th Conference of European Comparative Endocrinologists, Zurich, Switzerland (August 2012) 
  

	6.	a) How was the work reading to this Invention funded? (i.e. salaries, equipment used, supplies etc.) 

  

					
	 SPONSOR
	  	 PROJECT TITLE
	  	 RIS FUND #

	Protagenic Therapeutics Inc	  	 Existence for the existence of TCAP
 Receptors
in neurons
	  	457526

  

	b)	Was the project/work leading to this Invention subject to any software licence, material transfer, confidentiality, non-disclosure, collaboration or other agreement, written or oral, not referenced in (a) above
? 

x  NO     ̈  YES (please
provide details) 

	7.	Have any patent applications or other Intellectual property protection been filed in respect of this invention? 

	  	 ̈ NO         x YES (please provide details) 

 

	 	1.	AUSTRALIA: September 2010. Patent Number: (May 2,2003) 2003221575 Teneurin c-terminal associated peptides (tcap) and methods and uses thereof Inventors: LOVEJOY, David; CHEWPOY, R. Bradley; BARSYTE, Dalia; ROTZINGER,
Susan 

  

	 	2.	UNITED STATES. August 26, 2011. Patent Number 10/510959. Teneurin C-terminal peptides (TCAP) and uses thereof. LOVEJOY, David; CBEWPOY, R. Bradley; BARSYTE, Dalia; ROTZINGER, Susan. 

 

	8.	Warranty: 

 I/We. the Inventors listed in Section 2(a) , have read, understood and agree to all of
the preceding, and declare that all of the Information provided in this disclosure is complete and correct. To the best of our knowledge, all persons who might legally make an ownership claim in this Invention are identified in Section 2(a) and
2(b) 
  

									
	/s/ David A. Lovejoy	  		  	/s/ Dan S. Chand
	Signature	  	Date: 03/20/2013	  		  	Signature	  	Date: 03/20/2013
	 Typed Name:
  
	  	David A. Lovejoy	  		  	Typed Name:	  	Dhan S. Chand
	Signature	  	Date	  		  	Signature	  	Date
	Typed Name:	  		  		  	Typed Name:	  	

  

 SCHEDULE A (Continued) 

Status Listing of Patent Applications filed for the Improvements 

 

	
	 TENEURIN C- TERMINAL ASSOCIATED PEPTIDES (TCAP) AND METHODS AND USES THEREOF

	Inventors: LOVEJOY, David; CHEWPOY, R. Bradley; BARSYTE, Dalia; ROTZINGER, Susan

  

																	
	 COUNTRY
	  	REFERENCE#	  	TYPE	  	FILED	  	SERIAL #	  	ISSUED	  	PATENT #	  	STATUS
								
	 UNITED
 STATES
	  	T8476262USP1
 (090931-360625)
	  	OTH	  	05/03/2002	  	60/377,231	  		  		  	EXPIRED
								
	 UNITED
 STATES
	  	T8476262USP2
 (090931-360627)
	  	OTH	  	11/06/2002	  	60/424,016	  		  		  	EXPIRED
								
	WIPO	  	T8476262WO
 (090931-360635)
	  	CEQ	  	05/02/2003	  	PCT/
CA03/00622	  		  		  	ENTERED
 NATIONAL
 PHASE

								
	AUSTRALIA	  	T8476262AU
 (090931-360631)
	  	DCA	  	05/02/2003	  	2003221575	  	09/23/2011	  	2003221575	  	ISSUED
								
	CANADA	  	T8476262CA
 (090931-360629)
	  	DCA	  	05/02/2003	  	2,482,810	  	06/10/2014	  	2,482,810	  	ALLOWED
								
	 EUROPEAN
 PATENT
	  	T8476262EP
 (090931-360633)
	  	DCA	  	05/02/2003	  	03717086.7	  	03/12/2014	  	1499635	  	GRANTED
		
	 COMMENTS:
	  	Validated in France, Germany and Great Britain
 Opposition period is over; no opposition(s)
filed

						
	JAPAN	  	T8476262JP
 (090931-360634)
	  	DCA	  	05/02/2003	  	2004-501444	  	ABANDONED
								
	 UNITED
 STATES
	  	T8476262US
 (090931-360630)
	  	DCA	  	11/01/2004	  	10/510,959	  	01/03/2012	  	8,088,889	  	ISSUED
						
	 UNITED
 STATES
	  	T8476262USCON
 (090931-438501)
	  	CON	  	11/09/2011	  	13/292,849	  	PENDING

 A METHOD FOR INHIBITING NEURAL CELL DEATH 

Inventor: LOVEJOY, David 

															
	 
								
	 COUNTRY
	  	 REFERENCE#
	  	 TYPE
	  	 FILED
	  	 SERIAL #
	  	 ISSUED
	  	 PATENT #
	  	 STATUS

								
	 UNITED
 STATES
	  	 T8476261USP

(090931-370851)
	  	NEW	  	02/15/2006	  	60/773,309	  		  		  	EXPIRED
								
	 UNITED
 STATES
	  	 T8476261US

(090931-387536)
	  	 Non-
 provisional
	  	02/15/2007	  	11/706,376	  		  		  	ABANDONED
	 COMMENTS: This application was abandoned in lieu of filing a Continuation Application

  

															
	 UNITED
 STATES
	  	 T8476261USCON
 (090931-435930)
	  	CON	  	08/03/2011	  	13/197,575	  		  		  	ABANDONED
	 COMMENTS: July 1, 2014 – INSTRUCTIONS TO ABANDON APPLICATION RECEIVED

	 COMMENTS: This application is a Continuation of US application No. 11/706,376

 A METHOD FOR REGULATING NEURITE GROWTH 

Inventor: LOVEJOY, David 
  

															
								
	 COUNTRY
	  	 REFERENCE#
	  	 TYPE
	  	 FILED
	  	 SERIAL #
	  	 ISSUED
	  	 PATENT #
	  	 STATUS

								
	 UNITED
 STATES
	  	 T8476288USP

(090931-372046)
	  	NEW	  	03/21/2006	  	60/783,821	  		  		  	EXPIRED

 METHOD FOR MODULATING GLUCOSE TRANSPORT USING TENEURIN C-TERMINAL ASSOCIATE PEPTIDE (TCAP) 

Inventor: LOVEJOY, David; CHEN, Yani 
  

															
								
	 COUNTRY
	  	 REFERENCE#
	  	TYPE	  	FILED	  	SERIAL #	  	ISSUED	  	PATENT #	  	STATUS
								
	 UNITED
 STATES
	  	T8476302USP	  	Provisional	  	07/18/2014	  	62/026,346	  		  		  	PENDING

 TENEURIN C-TERMINAL ASSOCIATED PEPTIDE (TCAP) AS AN ANTAGONIST OF
LATROTOXIN 
 Inventor: LOVEJOY, David A; D’AQUILA, Andrea L. 
  

															
								
	 COUNTRY
	  	 REFERENCE#
	  	TYPE	  	FILED	  	SERIAL #	  	ISSUED	  	PATENT #	  	STATUS
								
	 UNITED
 STATES
	  	T8476314USP	  	Provisional	  		  		  		  		  	NOT FILED

  

 SCHEDULE B 

Additional Research Agreement (s) 
 Copies
of listed Sponsored Research Agreements Incorporated by Reference 
 Principal Investigator: David Alan Lovejoy 

 

											
						
	 S.No.
	  	 Research Agreement
	  	 Effective Date
	  	 End Date
	  	 Project Title
	  	 Fund Number

						
	1.	  	 Sponsored
 Research

Agreement
	  	Apr 1, 2012	  	March 31, 2013	  	Evidence for existence of TCAP receptors in neurons	  	495550
						
	2.	  	 Sponsored
 Research

Agreement
	  	Apr 1, 2013	  	March 31, 2014	  	Teneurin C-terminal Associated Peptide (TCAP)-mediated stress attenuation in vertebrates: Establishing the role of organismal and intracellular energy and glucose regulation and
metabolism	  	495550

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00254-of-00352.parquet"}]]